111 results on '"Hirotaka Matsumoto"'
Search Results
2. Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer
- Author
-
Yuki Sato, Hiromitsu Sumikawa, Ryota Shibaki, Takeshi Morimoto, Yoshihiko Sakata, Yuko Oya, Motohiro Tamiya, Hidekazu Suzuki, Hirotaka Matsumoto, Takashi Yokoi, Kazuki Hashimoto, Hiroshi Kobe, Aoi Hino, Megumi Inaba, Yoko Tsukita, Hideki Ikeda, Daisuke Arai, Hirotaka Maruyama, Satoshi Hara, Shinsuke Tsumura, Shinya Sakata, and Daichi Fujimoto
- Subjects
Pulmonary and Respiratory Medicine ,Cardiology and Cardiovascular Medicine ,Critical Care and Intensive Care Medicine - Published
- 2022
3. Influence of social isolation and loneliness on the prognosis of advanced lung cancer patients: a prospective cohort study
- Author
-
Tomoyasu Takemura, Yuki Kataoka, Nanami Ashi, Chigusa Shirakawa, Koya Okazaki, Azusa Sakurai, Takuma Imakita, Shunkichi Ikegaki, Hirotaka Matsumoto, Emiko Saito, Hirohito Takata, Sawako Kaku, Nobuko Wada, Mariko Shinomiya, Takehiro Otoshi, Masatoshi Shimada, Junichi Nikaido, Reika Iki, Katsuya Hirano, Tomoyuki Hirai, Kazuo Endo, Masataka Hirabayashi, and Toru Naganuma
- Subjects
Lung Neoplasms ,Social Isolation ,Oncology ,Loneliness ,Humans ,Prospective Studies ,Prognosis - Abstract
Purpose The purpose of this study was to investigate the impact of social isolation and loneliness on the overall survival and death at home in patients with lung cancer. Methods This prospective cohort study was conducted in a Japanese tertiary hospital. The enrollment period was from April 2018 to March 2020. Patients with pathologically diagnosed advanced lung cancer were included in this study. The primary outcome was overall survival, whereas the secondary outcome was death at home. The exposures were social isolation and loneliness. Results A total of 211 patients were enrolled and divided into two groups and further into quartiles according to their social isolation and loneliness level, respectively. The hazard ratios of social isolation were 1.65 (95% confidence interval; 1.12 to 2.44) and 1.87 (95% confidence interval; 1.15 to 3.03) in the univariate analysis, while 1.40 (95% confidence interval; 0.92 to 2.13) in the multivariate analysis with complete case and multiple imputation. The odds ratio of death at home with social isolation was 3.47 (95% confidence interval; 1.08 to 11.1) in the multivariate analysis with multiple imputation. Loneliness was not associated with overall survival or death at home. Conclusions Our study suggests that social isolation may be related to overall survival and death at home among patients with advanced lung cancer. More attention should be given to such patients at the time of diagnosis.
- Published
- 2022
4. Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation–positive non–small-cell lung cancer in a real-world setting (OSI-FACT)
- Author
-
Hirotaka Matsumoto, Hidekazu Suzuki, Yoko Tsukita, Daisuke Arai, Satoshi Hara, Takeshi Uenami, Motohiro Tamiya, Shinsuke Tsumura, Asuka Okada, Yoshihiko Sakata, Takashi Yokoi, Hideki Ikeda, Megumi Inaba, Yuki Sato, Shinya Sakata, Hirotaka Maruyama, Hiroshi Kobe, Go Saito, Takuro Sakagami, Jun Morinaga, Ryota Shibaki, and Yuko Oya
- Subjects
Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,Antineoplastic Agents ,Metastasis ,Cohort Studies ,Interquartile range ,Carcinoma, Non-Small-Cell Lung ,Internal medicine ,medicine ,Humans ,Osimertinib ,Progression-free survival ,Lung cancer ,Aged ,Retrospective Studies ,Acrylamides ,Aniline Compounds ,business.industry ,Hazard ratio ,Middle Aged ,medicine.disease ,Progression-Free Survival ,Confidence interval ,Discontinuation ,ErbB Receptors ,Treatment Outcome ,Female ,business - Abstract
Osimertinib is the standard of care in the initial treatment for advanced epidermal growth factor receptor (EGFR) mutation-positive lung cancer. However, clinical data and reliable prognostic biomarkers are insufficient.We performed a retrospective multicentre cohort study for 538 EGFR mutation-positive patients, who received osimertinib as the initial treatment between August 2018 and December 2019. The main outcome was progression-free survival (PFS).The median observation period was 14.7 months (interquartile range 11.4-20.0). The median PFS was 20.5 months (95% confidence interval [CI] 18.6-not reached). Multivariate analysis showed that sex (male) (hazard ratio [HR] 1.99, 95% CI 1.35-2.93, P = 0.001), malignant effusions (HR 1.51, 95% CI 1.11-2.04, P = 0.008), liver metastasis (HR 1.55, 95% CI 1.03-2.33, P = 0.037), advanced unresectable cases (HR 1.71, 95% CI, 1.04-2.82, P = 0.036), mutation type and programmed cell death-ligand 1 (PD-L1) expression were associated with PFS. The L858R (HR 1.55, 95% CI 1.01-2.38, P = 0.043) and uncommon mutations (HR 3.15, 95% CI 1.70-5.83, P 0.001) were associated with PFS. PD-L1 expression of 1-49% (HR 1.66, 95% CI 1.05-2.63, P = 0.029), ≥50% (HR 2.24, 95% CI 1.17-4.30, P = 0.015) and unknown (HR 1.53, 95% CI 1.05-2.22, P = 0.026) was associated with PFS. The main reasons for treatment discontinuation among 219 patients were disease progression (44.3%), pneumonitis (25.5%) and other adverse events (16.0%).During initial treatment with osimertinib, PD-L1 expression is significantly related to PFS. Adverse events are a noteworthy reason for discontinuation.
- Published
- 2021
5. Optimal Intravenous Administration Procedure for Efficient Delivery of Canine Adipose-Derived Mesenchymal Stem Cells
- Author
-
Yuyo Yasumura, Takahiro Teshima, Yoshiaki Taira, Takahiro Saito, Yunosuke Yuchi, Ryohei Suzuki, and Hirotaka Matsumoto
- Subjects
Inorganic Chemistry ,Organic Chemistry ,General Medicine ,adipose-derived mesenchymal stem cells ,canine ,cell delivery ,cell viability ,intravenous administration ,Physical and Theoretical Chemistry ,Molecular Biology ,Spectroscopy ,Catalysis ,Computer Science Applications - Abstract
Mesenchymal stem cells (MSC) are currently being investigated for their therapeutic applications in a wide range of diseases. Although many studies examined peripheral venous administration of MSC, few have investigated the detailed intravenous administration procedures of MSC from their preparation until they enter the body. The current study therefore aimed to explore the most efficient infusion procedure for MSC delivery by preparing and infusing them under various conditions. Canine adipose-derived mesenchymal stem cells (cADSC) were infused using different infusion apparatuses, suspension solutions, allogenic serum supplementation, infusion time and rates, and cell densities, respectively. Live and dead cell counts were then assessed by manual measurements and flow cytometry. Efficiency of live- and dead-cell infusion and cell viability were calculated from the measured cell counts and compared under each condition. Efficiency of live-cell infusion differed significantly according to the infusion apparatus, infusion rate, and combination of cell density and serum supplementation. Cell viability after infusion differed significantly between the infusion apparatuses. The optimal infusion procedure resulting in the highest cell delivery and viability involved suspending cADSC in normal saline supplemented with 5% allogenic serum at a density of 5 × 105 cells/mL, and infusing them using an automatic infusion device for 15 min. This procedure is therefore recommended as the standard procedure for the intravenous administration of ADSC in terms of cell-delivery efficiency.
- Published
- 2022
6. Immunomodulatory Effects of Canine Adipose Tissue Mesenchymal Stem Cell-Derived Extracellular Vesicles on Stimulated CD4+ T Cells Isolated from Peripheral Blood Mononuclear Cells
- Author
-
Hirotaka Matsumoto, Yunosuke Yuchi, Takahiro Teshima, Hidekazu Koyama, and Ryohei Suzuki
- Subjects
Article Subject ,biology ,Chemistry ,CD3 ,Immunology ,Mesenchymal stem cell ,Priming (immunology) ,General Medicine ,RC581-607 ,Peripheral blood mononuclear cell ,Cell biology ,Paracrine signalling ,Immune system ,biology.protein ,Immunology and Allergy ,Tumor necrosis factor alpha ,Immunologic diseases. Allergy ,CD8 - Abstract
Adipose tissue-derived mesenchymal stem cells (ADSCs) have anti-inflammatory and immunomodulatory characteristics. Many studies have suggested that the immunomodulation of ADSCs is largely mediated by secreted paracrine factors. Various factors are secreted from ADSCs, among which extracellular vesicles are considered to play a major role in the communication between ADSCs and target cells. Several studies have reported the function of canine ADSC-derived extracellular vesicles (cADSC-EVs), but few studies have reported the immunomodulatory effects of cADSC-EVs on immune cells. The purpose of this study was to investigate the effects of cADSC-EVs on in vitro-stimulated CD4+ T cells isolated from peripheral blood mononuclear cells (PBMCs). cADSC-EVs were isolated from cADSCs under naive conditions or primed conditions by tumor necrosis factor-α (TNFα) and interferon-γ (IFNγ). The expression levels of several microRNAs in cADSC-EVs were altered by priming with TNFα and IFNγ. Culturing PBMCs stimulated with concanavalin A in the presence of naive or primed cADSC-EVs inhibited the differentiation of PBMCs and CD4+ T cells and promoted apoptosis of PBMCs. CD4+, CD8+, and CD4+CD8+ T cells were decreased, while CD3+CD4-CD8- T cells were increased. T helper (Th) 1, Th2, Th17, and regulatory T (Treg) cells were analyzed by flow cytometry. cADSC-EVs inhibited the proliferation of Th1 and Th17 cells and enhanced Th2 and Treg cell proliferation. However, CD4+ T cells that had incorporated labeled cADSC-EVs comprised only a few percent of all cells. Therefore, these responses of stimulated CD4+ T cells may be due to not only direct effects of cADSC-EVs but also to indirect effects through interactions between cADSC-EVs and other immune cells. In conclusion, cADSC-EVs exert immunosuppressive effects on stimulated CD4+ T cells in vitro. These findings may be useful for further studies of immune diseases.
- Published
- 2021
7. Systemic Metabolic Alteration Dependent on the Thyroid-Liver Axis in Early PD
- Author
-
Kengo Miyamoto, Shinji Saiki, Hirotaka Matsumoto, Ayami Suzuki, Yuri Yamashita, Tatou Iseki, Shin‐Ichi Ueno, Kenta Shiina, Tetsushi Kataura, Koji Kamagata, Yoko Imamichi, Yukiko Sasazawa, Motoki Fujimaki, Wado Akamatsu, and Nobutaka Hattori
- Subjects
Neurology ,Neurology (clinical) - Abstract
Parkinson's disease (PD) is a common neurodegenerative disease characterized by initial involvement of the olfactory bulb/amygdala or autonomic nerves followed by nigral degeneration. Although autonomic innervation strictly regulates multiorgan systems, including endocrine functions, circulation, and digestion, how dysautonomia in PD affects systemic metabolism has not been identified. In this study, we tried to estimate the pathogenic linkage of PD by nuclear medicine techniques, trans-omic analysis of blood samples, and cultured cell experiments.Thyroid mediastinum ratio ofSympathetic denervation of thyroid correlating with its cardiac denervation was confirmed in 1,158 patients with PD by MIBG scintigraphy. Among patients with drug-naïve PD, comprehensive metabolome analysis revealed decreased levels of thyroxine and insufficient fatty acid β-oxidation, which positively correlate with one another. Likewise, both plasma metabolome data and transcriptome data of circulating exosomal miRNAs, revealed specific enrichment of the peroxisome proliferator-activated receptor (PPARα) axis. Finally, association of thyroid hormone with PPARα-dependent β-oxidation regulation was confirmed by in vitro experiments.Our findings suggest that interorgan communications between the thyroid and liver are disorganized in the early stage of PD, which would be a sensitive diagnostic biomarker for PD. ANN NEUROL 2022.
- Published
- 2022
8. Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: A multicentre retrospective cohort study
- Author
-
Mihoko Imaji, Daichi Fujimoto, Yuki Sato, Yoshihiko Sakata, Yuko Oya, Motohiro Tamiya, Hidekazu Suzuki, Hideki Ikeda, Takashi Kijima, Hirotaka Matsumoto, Masaki Kanazu, Aoi Hino, Megumi Inaba, Yoko Tsukita, Daisuke Arai, Hirotaka Maruyama, Satoshi Hara, Shinsuke Tsumura, Hiroshi Kobe, Hiromitsu Sumikawa, Shinya Sakata, and Nobuyuki Yamamoto
- Subjects
Cancer Research ,Oncology - Abstract
Although osimertinib is a standard first-line treatment for patients with advanced-stage non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations, the incidence rate of pneumonitis associated with osimertinib is high. However, there are few reports about the safety and efficacy of osimertinib rechallenge after the development of pneumonitis.We conducted a retrospective multicentre cohort study of consecutive patients who developed pneumonitis associated with osimertinib as a first-line and received osimertinib rechallenge. The primary outcome was the incidence rate of any grade pneumonitis after osimertinib rechallenge. The secondary outcome was treatment efficacy in patients after osimertinib rechallenge.In total, 33 patients who received osimertinib rechallenge were included. Of them, 26 patients had grade 1, 6 patients had grade 2, and 1 patient had grade 3 initial pneumonitis. The median follow-up period after the osimertinib rechallenge was 16.9 months (interquartile range, 11.1-21.3 months). After the start of osimertinib rechallenge, five patients (15%) experienced mild relapsed pneumonitis. Three of the five patients had similar imaging patterns for initial and relapsed pneumonitis. No significant differences in characteristics were observed between patients with and without relapsed pneumonitis. The median progression-free survival after osimertinib rechallenge was not achieved (95% confidence interval: 10.3 months - not reached).Osimertinib rechallenge was feasible and effective for patients who developed initial pneumonitis associated with first-line osimertinib therapy. Osimertinib might be considered a treatment option even after the development of mild initial pneumonitis.
- Published
- 2022
9. Influence of loneliness and social isolation on the diagnosis and treatment of Japanese patients with advanced lung cancer: a prospective cohort study
- Author
-
Yuki Kataoka, Azusa Sakurai, Shunkichi Ikegaki, Emiko Saito, Nobuko Wada, Masatoshi Shimada, Reika Iki, Takehiro Otoshi, Sawako Kaku, Takuma Imakita, Mariko Shinomiya, Koya Okazaki, Hirohito Takata, Katsuya Hirano, Hirotaka Matsumoto, Toru Naganuma, Tomoyasu Takemura, Masataka Hirabayashi, Kazuo Endo, Junichi Nikaido, Chigusa Shirakawa, and Tomoyuki Hirai
- Subjects
medicine.medical_specialty ,Lung Neoplasms ,Gene mutation ,Tertiary referral hospital ,03 medical and health sciences ,0302 clinical medicine ,Japan ,Internal medicine ,medicine ,Humans ,Prospective Studies ,030212 general & internal medicine ,Social determinants of health ,Social isolation ,Lung cancer ,Prospective cohort study ,Advanced and Specialized Nursing ,Performance status ,business.industry ,Loneliness ,medicine.disease ,Anesthesiology and Pain Medicine ,Social Isolation ,030220 oncology & carcinogenesis ,medicine.symptom ,business - Abstract
Background Social determinants of health (SDHs) are social factors that affect human health; loneliness and social isolation are core SDH factors. There is a possibility that SDHs are related to passive decisionmaking. However, few studies have evaluated SDHs, especially social isolation and loneliness, among lung cancer patients. This study aims to investigate the effects of social isolation and loneliness on the diagnosis and treatment of Japanese lung cancer patients. Methods This is a prospective cohort study that was conducted in a tertiary referral hospital in Japan (University Hospital Medical Information Network registration: UMIN000031810). The enrollment period was between April 2018 and March 2020. Patients with clinical and/or pathological diagnosis of lung cancer were enrolled in this study. Exposures were social isolation and loneliness, and main outcomes were diagnosis methods and whether the initial treatment involved active therapy or best supportive care (BSC). The confounding factors were defined as sex, age, smoking status, respiratory symptoms, weight loss, presentation with any symptoms, Eastern Cooperative Oncology Group (ECOG) performance status, tumor nodes metastasis (TNM) classification, driver gene mutations [i.e., epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK)], and programmed death-ligand 1 (PD-L1) tumor proportion score. Results The study enrolled 264 patients who were divided into quartiles according to their loneliness scores and into two groups according to the social isolation level. Univariate analysis, complete case analysis, and multivariate analysis with multiple imputation failed to detect significant differences in diagnostic method or initial treatment strategy according to loneliness or social isolation level. Conclusions Physicians may not need to consider a patient's loneliness and/or social isolation when diagnosing lung cancer and selecting treatment under universal health insurance coverage. Further studies are needed to understand the influences of loneliness and social isolation on the prognosis of lung cancer patients.
- Published
- 2021
10. Letter to the editor regarding the study 'The effectiveness of gabapentin and gabapentin/montelukast combination compared with dextromethorphan in the improvement of COVID‐19‐related cough: A randomized, controlled clinical trial'
- Author
-
Shun Ito, Yushi Shimamura, and Hirotaka Matsumoto
- Subjects
Pulmonary and Respiratory Medicine ,Immunology and Allergy ,Genetics (clinical) - Published
- 2022
11. PhyGraFT: a network-based method for phylogenetic trait analysis
- Author
-
Hirotaka Matsumoto and Motomu Matsui
- Abstract
With the determination of numerous viral and bacterial genome sequences, phylogeny-trait associations are now being studied. In these studies, phylogenetic trees were first reconstructed, and trait data were analyzed based on the reconstructed tree. However, in some cases, such as fast evolution sequences and gene-sharing network data, reconstructing the phylogenetic tree is challenging. In such cases, network-thinking, instead of tree-thinking, is gaining attention. Here, we propose a novel network-thinking approach, PhyGraFT, to analyze trait data from the network. We validated that PhyGraFT can find phylogenetic signals and associations of traits with the simulation dataset. We applied PhyGraFT for influenza type A and virome gene-sharing datasets. As a result, we identified several evolutionary structures and their associated traits. Our approach is expected to provide novel insights into network-thinking not only for typical phylogenetics but also for various biological data, such as antibody evolution.
- Published
- 2022
12. Early embryonic mutations reveal dynamics of somatic and germ cell lineages in mice
- Author
-
Arikuni Uchimura, Hirotaka Matsumoto, Yasunari Satoh, Yohei Minakuchi, Sayaka Wakayama, Teruhiko Wakayama, Mayumi Higuchi, Masakazu Hashimoto, Ryutaro Fukumura, Atsushi Toyoda, Yoichi Gondo, and Takeshi Yagi
- Subjects
Mice ,Germ Cells ,Mutation Rate ,Zygote ,Mutation ,Genetics ,Animals ,Cell Lineage ,Genetics (clinical) - Abstract
De novo mutations accumulate with zygotic cell divisions. However, the occurrence of these mutations and the way they are inherited by somatic cells and germ cells remain unclear. Here, we present a novel method to reconstruct cell lineages. We identified mosaic mutations in mice using deep whole-genome sequencing and reconstructed embryonic cell lineages based on the variant allele frequencies of the mutations. The reconstructed trees were confirmed using nuclear transfer experiments and the genotyping of approximately 50 offspring of each tree. The most detailed tree had 32 terminal nodes and showed cell divisions from the fertilized egg to germ cell– and somatic cell–specific lineages, indicating at least five independent cell lineages that would be selected as founders of the primordial germ cells. The contributions of each lineage to germ cells and offspring varied widely. At the emergence of the germ cell–specific lineages, 10–15 embryonic mutations had accumulated, suggesting that the pregastrulation mutation rate is 1.0 mutation per mitosis. Subsequent mutation rates were 0.7 for germ cells and 13.2 for tail fibroblasts. Our results show a new framework to assess embryonic lineages; further, we suggest an evolutionary strategy for preserving heterogeneity owing to postzygotic mutations in offspring.
- Published
- 2022
13. Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial Eligibility
- Author
-
Daichi Fujimoto, Takeshi Morimoto, Motohiro Tamiya, Akito Hata, Hirotaka Matsumoto, Atsushi Nakamura, Toshihide Yokoyama, Yoshihiko Taniguchi, Junji Uchida, Yuki Sato, Takashi Yokoi, Hisashi Tanaka, Naoki Furuya, Takeshi Masuda, Yoshihiko Sakata, Eisaku Miyauchi, Satoshi Hara, Go Saito, Satoru Miura, Masaki Kanazu, Nobuyuki Yamamoto, and Hiroaki Akamatsu
- Subjects
General Medicine - Abstract
ImportanceChemoimmunotherapy is the standard first-line therapy for patients with extensive-stage small cell lung cancer (ES-SCLC). However, whether findings from pivotal trials can be extrapolated to the clinical practice setting remains unclear.ObjectiveTo compare treatment outcome gaps following first-line chemoimmunotherapy for patients with ES-SCLC between those who met and did not meet the eligibility criteria used in previous clinical trials.Design, Setting, and ParticipantsA prospective cohort study was conducted from September 1, 2019, to September 30, 2020, at 32 hospitals in Japan, with at least 12 months of follow-up. Participants included consecutive patients with ES-SCLC who received carboplatin and etoposide with atezolizumab as first-line therapy.ExposuresPatients who met eligibility criteria for pivotal phase 3 clinical trials were considered trial-eligible.Main Outcomes and MeasuresThe primary outcome was 6-month progression-free survival. The secondary outcomes were differences in progression-free survival, overall survival, and safety according to whether key clinical trial eligibility criteria were met.ResultsA total of 207 patients were analyzed (median age, 72 years; range, 46-87 years; 170 [82%] were male). Sixty-four patients (31%) were older adults (age ≥75 years), and most (184 [89%]) had an Eastern Cooperative Oncology Group performance status of 0 or 1. There were 132 (64%) trial-eligible patients. The 6-month progression-free survival rate for all patients was 38.8% (95% CI, 32.4%-45.7%). The median progression-free survival was 5.1 months in trial-eligible patients and 4.7 months in trial-ineligible patients (hazard ratio, 0.72; 95% CI, 0.53-0.97; P = .03). The proportion of patients who achieved disease control was 93% (118 of 127) in trial-eligible patients and 77% (55 of 71) in trial-ineligible patients (P = .002). The median overall survival was 15.8 months in trial-eligible patients and 13.1 months in trial-ineligible patients (hazard ratio, 0.73; 95% CI, 0.51-1.07; P = .10). The rate of severe adverse events was numerically higher among trial-ineligible patients than among trial-eligible patients (39% vs 27%; P = .07).Conclusions and RelevanceIn this cohort study, the overall treatment outcome was comparable to that reported in pivotal clinical trials. However, treatment outcomes after chemoimmunotherapy might differ between trial-eligible and trial-ineligible patients. These findings suggest that trial-eligibility criteria may be useful in clinical practice, and further studies using data from clinical practice settings are required to inform regulatory approval and clinical decision-making.
- Published
- 2023
14. Minimally invasive current-controlled electrical stimulation system for bacteria using highly capacitive conducting polymer-modified electrodes
- Author
-
Daiki, Makino, Aoba, Ueki, Hirotaka, Matsumoto, and Kuniaki, Nagamine
- Subjects
Bacteria ,Polymers ,Electrochemistry ,Biophysics ,General Medicine ,Physical and Theoretical Chemistry ,Electrodes ,Electric Stimulation - Abstract
This paper proposes a minimally invasive current-controlled electric stimulation system based on a poly(3,4-ethylenedioxythiophene) (PEDOT)-modified electrode to characterize the dynamics of the membrane potential in Bacillus subtilis. A highly capacitive PEDOT-modified electrode enabled the injection of a large ionic charge to the surface of the cells suppressing cytotoxic pH change in the vicinity of the electrode. The current pulse induced a hyperpolarization response in B. subtilis around the electrode. Using quantitative charge injection through current-controlled electrical stimulation, the threshold charge density to excite B. subtilis was roughly estimated to be 530.8 µC cm
- Published
- 2023
15. Right ventricular systolic and diastolic function assessed by two-dimensional speckle tracking echocardiography in dogs with myxomatous mitral valve disease
- Author
-
Ryohei Suzuki, Hirotaka Matsumoto, Yunosuke Yuchi, Takahiro Teshima, and Hidekazu Koyama
- Subjects
medicine.medical_specialty ,Heart Ventricles ,canine ,Speckle tracking echocardiography ,Disease ,right ventricular myocardial performance index ,Muscle hypertrophy ,Dogs ,Internal medicine ,Internal Medicine ,medicine ,Animals ,Diastolic function ,Dog Diseases ,Myxomatous mitral valve ,Full Paper ,General Veterinary ,business.industry ,post-capillary pulmonary hypertension ,medicine.disease ,Pulmonary hypertension ,Comorbidity ,congestive heart failure ,Echocardiography ,Heart failure ,Ventricular Function, Right ,Cardiology ,Mitral Valve ,business - Abstract
Pulmonary hypertension (PH) is a common comorbidity in dogs with myxomatous mitral valve disease (MMVD), and can induce various changes in the right heart, such as right ventricular (RV) hypertrophy, dilatation, and dysfunction. We hypothesized that RV function, not only systolic function but also diastolic function, could be worsened with PH progression. We aimed to compare RV systolic and diastolic function in dogs with MMVD. Twenty healthy dogs and sixty-eight dogs with MMVD were enrolled. Dogs with MMVD were classified into the probability of PH. Two-dimensional and Doppler echocardiographic indices for right heart and two-dimensional speckle tracking echocardiography indices were measured. The morphological indicators of the right heart were significantly higher only in the high probability of PH group. The RV strain, early-diastolic and systolic strain rates were significantly lower in the high probability of PH group than those in the low and intermediate probability of PH groups. Multivariate analysis showed that increased RV internal dimension normalized by body weight and RV myocardial performance index were significantly associated with the presence of right-sided congestive heart failure. Speckle tracking echocardiography-derived RV systolic and diastolic function were activated in the low and intermediate probability of PH groups. However, dogs with high probability of PH showed RV myocardial dysfunction and dilatation. Increased RV myocardial performance index and end-diastolic RV internal dimension normalized by body weight were significantly associated with the presence of right-sided congestive heart failure in dogs with MMVD.
- Published
- 2021
16. Utility of tricuspid annular plane systolic excursion normalized by right ventricular size indices in dogs with postcapillary pulmonary hypertension
- Author
-
Yunosuke Yuchi, Hirotaka Matsumoto, Takahiro Teshima, Hidekazu Koyama, and Ryohei Suzuki
- Subjects
medicine.medical_specialty ,Heart Ventricles ,Hypertension, Pulmonary ,Ventricular Dysfunction, Right ,Cardiology ,canine ,Internal dimension ,Speckle tracking echocardiography ,Standard Article ,myxomatous mitral valve disease ,Dogs ,Internal medicine ,Animals ,Medicine ,General Veterinary ,Ventricular size ,business.industry ,Area under the curve ,Reproducibility of Results ,medicine.disease ,Standard Articles ,right ventricular function ,Echocardiography ,Postcapillary pulmonary hypertension ,Heart failure ,Rv function ,Ventricular Function, Right ,SMALL ANIMAL ,business ,Wall thickness - Abstract
Background Tricuspid annular plane systolic excursion (TAPSE) is a common right ventricular (RV) function indicator. However, TAPSE was not decreased in dogs with myxomatous mitral valve disease (MMVD) and postcapillary pulmonary hypertension (PH) because of its load, angle, and body weight dependency, and TAPSE was considered a preload‐dependent index. Objectives To evaluate the utility of TAPSE normalized by RV size in dogs with postcapillary PH. Animals Twenty healthy dogs and 71 MMVD dogs with or without PH. Methods In this prospective observational study, end‐diastolic RV internal dimension (RVIDd), end‐diastolic and end‐systolic RV area, and end‐diastolic RV wall thickness were measured as RV size indices. The TAPSE was measured using B‐mode and M‐mode methods. Normalized TAPSE was calculated by dividing TAPSE by each RV size index. The RV strain was obtained as the detailed RV function using 2‐dimensional speckle tracking echocardiography. All indices were compared among the PH severity groups and in the presence of right‐sided congestive heart failure (R‐CHF). Results Although nonnormalized TAPSE was higher with PH severity progression, each normalized TAPSE showed a significant decrease in the severe PH group (P
- Published
- 2020
17. Factors Influencing Social Isolation and Loneliness Among Lung Cancer Patients: A Cross-sectional Study
- Author
-
Masatoshi Shimada, Emiko Saito, Takuma Imakita, Nobuko Wada, Masataka Hirabayashi, Hirohito Takata, Reika Iki, Koya Okazaki, Chigusa Shirakawa, Sawako Kaku, Takehiro Otoshi, Nanami Ashi, Kazuo Endo, Tomoyasu Takemura, Katsuya Hirano, Junichi Nikaido, Toru Naganuma, Hirotaka Matsumoto, Yuki Kataoka, Azusa Sakurai, Shunkichi Ikegaki, Mariko Shinomiya, and Tomoyuki Hirai
- Subjects
Adult ,Male ,Gerontology ,Cancer Research ,Lung Neoplasms ,Cross-sectional study ,media_common.quotation_subject ,Care provision ,medicine ,Humans ,Dementia ,Social determinants of health ,Social isolation ,Aged ,media_common ,Aged, 80 and over ,business.industry ,Loneliness ,General Medicine ,Middle Aged ,medicine.disease ,UCLA Loneliness Scale ,Cross-Sectional Studies ,Social Isolation ,Oncology ,Female ,medicine.symptom ,business ,Welfare - Abstract
Background/aim Previous reviews of Social determinants of health in lung cancer patients have not examined essential factors such as social isolation and loneliness. This study aimed to explore the factors affecting social isolation and loneliness among lung cancer patients. Patients and methods A cross-sectional study was conducted. Social isolation, loneliness, and the presence of dementia were measured using Japanese adaptations of the Lubben Social Network Scale, UCLA Loneliness Scale, and Life Function Evaluation for Care Provision, respectively. Results From March 2019 to March 2020, 264 patients were included. Social isolation was significantly higher for patients receiving welfare (adjusted OR=5.28, 95% CI=2.24-12.4). Loneliness was significantly higher for patients receiving welfare (beta coefficient=0.52, 95% Cl=0.13-0.90) with symptoms of dementia (beta coefficient=0.28, 95% Cl=0.03-0.54). Conclusion Results showed that receiving welfare was associated with experiencing social isolation. Receiving welfare and symptoms of dementia were associated with experiencing loneliness.
- Published
- 2020
18. Investigation of Beraprost Sodium on Cardiac Function and Hemodynamics in Canine Models of Chronic Pulmonary Hypertension
- Author
-
Ryohei Suzuki, Yunosuke Yuchi, Takahiro Saito, Takahiro Teshima, Hirotaka Matsumoto, and Hidekazu Koyama
- Subjects
General Veterinary ,urologic and male genital diseases ,hormones, hormone substitutes, and hormone antagonists - Abstract
Pulmonary hypertension (PH) is a life-threatening disease in dogs characterized by increased pulmonary arterial pressure (PAP) and/or pulmonary vascular resistance. No study has evaluated the utility of Beraprost sodium (BPS) in dogs with PH. This study aimed to evaluate the effect of BPS on cardiac function and hemodynamics and examine the optimal dose of BPS in canine models of chronic embolic PH. In this prospective crossover study, three doses of BPS (5, 15, and 25 μg/kg, twice a day) were examined in eight canine models of chronic embolic PH. All model dogs underwent invasive PAP measurement, echocardiography, and non-invasive systemic blood pressure measurement before and after continuous administration of oral BPS for 1 week. No side effects of BPS were observed in any dog during the study. All doses of BPS significantly decreased systolic PAP and pulmonary vascular impedance. Additionally, systemic vascular impedance significantly decreased with 15 and 25 μg/kg of BPS. The right ventricular stroke volume and longitudinal strain significantly decreased with all doses of BPS. The left ventricular stroke volume and circumferential strain decreased with 15 μg/kg BPS. BPS was well-tolerated in this study. A dose-dependent vasodilating effect on pulmonary vessels was observed in canine models of chronic PH. Additionally, 15 μg/kg BPS showed a balanced vasodilating effect on systemic and pulmonary vessels. Furthermore, with a decrease in systemic and pulmonary vascular impedance, the left and right ventricular functions were significantly improved. Our results suggest that BPS may be useful in the treatment of canine PH.
- Published
- 2022
19. MOCCS profile analysis clarifies the cell type dependency of transcription factor-binding sequences and cis-regulatory SNPs in humans
- Author
-
Saeko Tahara, Takaho Tsuchiya, Hirotaka Matsumoto, and Haruka Ozaki
- Subjects
genetic processes ,natural sciences - Abstract
Transcription factors (TFs) show heterogeneous DNA-binding specificities in individual cells and whole organisms in natural conditions): de novo motif discovery usually provides multiple motifs even from a single ChIP-seq sample. Despite the accumulation of ChIP-seq data and ChIP-seq-derived motifs, the diversity of DNA-binding specificities across different TFs and cell types remains largely unexplored. Here, we propose MOCCS profiles, the new representation of DNA-binding specificity of TFs, which describes a ChIP-seq sample as a profile of TF-binding specificity scores (MOCCS2scores) for every k-mer sequence. Using our k-mer-based motif discovery method MOCCS2, we systematically computed MOCCS profiles for >10,000 human TF ChIP-seq samples across diverse TFs and cell types. Comparison of MOCCS profiles revealed the global distributions of DNA-binding specificities, and found that one-third of the analyzed TFs showed differences in DNA-binding specificities across cell types. Moreover, we showed that the differences in MOCCS2scores (ΔMOCCS2scores) predicted the effect of variants on TF binding, validated by in vitro and in vivo assay datasets. We also demonstrate ΔMOCCS2scores can be used to interpret non-coding GWAS-SNPs as TF-affecting SNPs and provide their candidate responsible TFs and cell types. Our study provides the basis for investigating gene expression regulation and non-coding disease-associated variants in humans.
- Published
- 2022
20. Prospective multicenter cohort study of durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis
- Author
-
Takeya Sugimoto, Daichi Fujimoto, Yuki Sato, Motohiro Tamiya, Takashi Yokoi, Yoshihiko Taniguchi, Aoi Hino, Akito Hata, Junji Uchida, Yasushi Fukuda, Satoshi Hara, Masaki Kanazu, Hirotaka Matsumoto, Masaki Kokubo, and Nobuyuki Yamamoto
- Subjects
Pulmonary and Respiratory Medicine ,Radiation Pneumonitis ,Cancer Research ,Antineoplastic Agents, Immunological ,Lung Neoplasms ,Oncology ,Carcinoma, Non-Small-Cell Lung ,Antibodies, Monoclonal ,Humans ,Chemoradiotherapy ,Pneumonia ,Prospective Studies - Abstract
Durvalumab was safe and effective in patients with unresectable stage III non-small cell lung cancer (NSCLC) after concurrent chemoradiotherapy (CCRT) in a phase 3 trial (PACIFIC trial). Although a history of radiation pneumonitis (RP) has been reported to increase the risk of exacerbation of pneumonitis associated with programmed death-1 axis inhibitors, the detailed clinical results of durvalumab treatment in patients with baseline grade 1 RP were not reported in the PACIFIC trial. Therefore, we aimed to evaluate the safety and effectiveness of durvalumab therapy in these patients.This was a multicenter prospective cohort study involving 35 patients. Patients were eligible if they met the following criteria: inoperable stage III NSCLC, administration of durvalumab within 42 days after CCRT using platinum-based chemotherapy, no disease progression after CCRT, Eastern Cooperative Oncology Group performance status of 0-1, and presence of grade 1 RP at baseline. We assessed the effectiveness and safety of durvalumab with a minimum 1-year follow-up period for all patients.Thirty-five patients were enrolled in our study from February 2019 to December 2019. The median progression-free survival was 11.4 months (95 % confidence interval, 7.1 months-not reached), and the median overall survival was not reached. Eleven (31 %) patients had grade ≥2 pneumonitis/RP, 10 (28 %) developed grade 2 pneumonitis/RP, and 1 (3 %) developed grade 5 pneumonitis/RP. Five (14 %) patients experienced treatment-related grade ≥3 adverse events.Durvalumab might be safe and effective in patients with stage III NSCLC with baseline grade 1 RP following chemoradiotherapy.
- Published
- 2022
21. DDBJ Data Analysis Challenge: a machine learning competition to predict Arabidopsis chromatin feature annotations from DNA sequences
- Author
-
Hisashi Kashima, Masahiro Mochizuki, Shinya Oki, Toshihisa Takagi, Hirotaka Matsumoto, Osamu Ogasawara, Takuya Kato, Takatomo Fujisawa, Haruka Ozaki, Masanori Arita, Yukino Baba, Yasukazu Nakamura, Toshitsugu Okayama, and Eli Kaminuma
- Subjects
0106 biological sciences ,0303 health sciences ,Process (engineering) ,business.industry ,Deep learning ,General Medicine ,Gene Annotation ,Biology ,Machine learning ,computer.software_genre ,Crowdsourcing ,010603 evolutionary biology ,01 natural sciences ,Task (project management) ,03 medical and health sciences ,Annotation ,Genetics ,Feature (machine learning) ,Domain knowledge ,Artificial intelligence ,business ,Molecular Biology ,computer ,030304 developmental biology - Abstract
Recently, the prospect of applying machine learning tools for automating the process of annotation analysis of large-scale sequences from next-generation sequencers has raised the interest of researchers. However, finding research collaborators with knowledge of machine learning techniques is difficult for many experimental life scientists. One solution to this problem is to utilise the power of crowdsourcing. In this report, we describe how we investigated the potential of crowdsourced modelling for a life science task by conducting a machine learning competition, the DNA Data Bank of Japan (DDBJ) Data Analysis Challenge. In the challenge, participants predicted chromatin feature annotations from DNA sequences with competing models. The challenge engaged 38 participants, with a cumulative total of 360 model submissions. The performance of the top model resulted in an area under the curve (AUC) score of 0.95. Over the course of the competition, the overall performance of the submitted models improved by an AUC score of 0.30 from the first submitted model. Furthermore, the 1st- and 2nd-ranking models utilised external data such as genomic location and gene annotation information with specific domain knowledge. The effect of incorporating this domain knowledge led to improvements of approximately 5%-9%, as measured by the AUC scores. This report suggests that machine learning competitions will lead to the development of highly accurate machine learning models for use by experimental scientists unfamiliar with the complexities of data science.
- Published
- 2020
22. Detection of Congestive Heart Failure and Myocardial Dysfunction in Cats With Cardiomyopathy by Using Two-Dimensional Speckle-Tracking Echocardiography
- Author
-
undefined undefined, Hidekazu Koyama, Hirotaka Matsumoto, Takahiro Teshima, Haruka Kanno, Yunosuke Yuchi, Takahiro Saito, and Ryohei Suzuki
- Published
- 2022
23. Improvement in Clinical Symptoms and Fecal Microbiome After Fecal Microbiota Transplantation in a Dog with Inflammatory Bowel Disease
- Author
-
Yasushi Kataoka, Ryohei Suzuki, Yunosuke Yuchi, Takahiro Teshima, Hidekazu Koyama, Ryoko Kibe, Hirotaka Matsumoto, and Ayaka Niina
- Subjects
medicine.medical_specialty ,040301 veterinary sciences ,medicine.medical_treatment ,canine ,microbiome ,Case Report ,Gastroenterology ,Inflammatory bowel disease ,diversity ,0403 veterinary science ,Duodenitis ,inflammatory bowel disease ,Internal medicine ,Medicine ,Microbiome ,Feces ,business.industry ,0402 animal and dairy science ,fecal microbiota transplantation ,dysbiosis ,04 agricultural and veterinary sciences ,Enema ,medicine.disease ,040201 dairy & animal science ,Diarrhea ,Vomiting ,medicine.symptom ,business ,Dysbiosis - Abstract
Purpose Recently, fecal microbiota transplantation (FMT) has been tested in veterinary medicine as a treatment option for multiple gastrointestinal (GI) diseases, such as inflammatory bowel disease (IBD). However, there are no reports of changes in the microbial diversity of fecal microbiome after treatment with FMT in canine IBD cases. Moreover, little is known about the long-term efficacy and safety of FMT treatment for dogs. Herein, we present a case of canine intractable IBD treated with repeated, long-term FMT. Patients and methods The patient was a 10-year-old, neutered, male, 4-kg Toy Poodle with a prolonged history of vomiting and diarrhea. Fecal examination for pathogens was negative. Despite treatment with multiple antibacterial and antidiarrheal agents, the patient showed no improvement. Endoscopic mucus sampling diagnosed a case of lymphocytic-plasmacytic duodenitis, ie, idiopathic IBD. Eventually, we performed periodic, long-term fecal microbiota transplantation of fresh donor feces collected from a 4-year-old, 32.8-kg, neutered male Golden Retriever by rectal enema. Additionally, we performed 16S rRNA sequence analysis, before and after FMT, to evaluate the microbiome diversity. Results Fecal microbiome diversity after FMT resembled that of the healthy donor dog’s fecal microbiome, before FMT, which led us to conclude that the fecal microbiome in our patient normalized with FMT. Moreover, the clinical symptoms improved remarkably with regard to the changes in the fecal microbiome. Additionally, we noted no observable side effects during FMT treatment. Conclusion This report indicates the efficacy and safety of long-term, periodic FMT for a case of canine IBD based on attenuation of clinical symptoms and changes in fecal microbiome diversity. Therefore, FMT could be chosen as a treatment option for IBD in canines in the future.
- Published
- 2019
- Full Text
- View/download PDF
24. Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non–small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study
- Author
-
Akihiro Tamiya, Tomonori Hirashima, Nobuhiko Sawa, Ryota Kominami, Toshihide Yokoyama, Hidekazu Suzuki, Daichi Fujimoto, Junji Uchida, Masaki Kanazu, Satoshi Hara, Hirotaka Matsumoto, Kazutaka Hosoya, Mitsunori Morita, Hayato Kawachi, Yasushi Fukuda, Motohiro Tamiya, Takeshi Makio, Toru Kumagai, Katsuya Hirano, and Seigo Ishii
- Subjects
Adult ,Male ,0301 basic medicine ,Oncology ,medicine.medical_specialty ,Lung Neoplasms ,Pembrolizumab ,Adenocarcinoma ,Antibodies, Monoclonal, Humanized ,B7-H1 Antigen ,Metastasis ,03 medical and health sciences ,Antineoplastic Agents, Immunological ,0302 clinical medicine ,Carcinoma, Non-Small-Cell Lung ,Internal medicine ,Biomarkers, Tumor ,Humans ,Medicine ,Malignant pleural effusion ,Pharmacology (medical) ,Lung cancer ,Response Evaluation Criteria in Solid Tumors ,Aged ,Retrospective Studies ,Aged, 80 and over ,Pharmacology ,business.industry ,Hazard ratio ,Bone metastasis ,Retrospective cohort study ,Middle Aged ,Prognosis ,medicine.disease ,Survival Rate ,030104 developmental biology ,030220 oncology & carcinogenesis ,Carcinoma, Squamous Cell ,Female ,business ,Follow-Up Studies - Abstract
Associations between treatment outcomes of immune checkpoint inhibitors and metastatic sites in advanced non-small cell lung cancer (NSCLC) are not well known. Therefore, this multicenter retrospective study aimed to investigate the predictive factors of metastatic sites after first-line pembrolizumab treatment for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%. We retrospectively analyzed advanced NSCLC patients with a PD-L1 TPS ≥50% who underwent first-line pembrolizumab therapy at 11 institutions between February 2017 and April 2018. Clinical data collected from medical records included metastatic sites at the time of pembrolizumab treatment. Treatment outcomes of pembrolizumab were assessed according to the Response Evaluation Criteria in Solid Tumors, version 1.1. In total, 213 patients were included in the study. The median age was 71 years (range 39-91 years). Of the 213 patients, 176 (83%) were men and 172 (81%) had an Eastern Cooperative Oncology Group performance status (ECOG-PS) score of 0-1. The most common metastases were thoracic lymph node metastasis (77%), intrapulmonary metastasis (31%), bone metastasis (28%), and malignant pleural effusion (26%). On multivariate analysis, a poor ECOG-PS score (hazard ratio: 1.95, 95.0% confidence interval: 1.25-3.04; P = 0.003) and malignant pleural effusion (hazard ratio: 1.52, 95.0% confidence interval: 1.01-2.29; P = 0.043) were independent predictors of shorter progression-free survival in patients treated with pembrolizumab. For NSCLC patients with malignant pleural effusion, pembrolizumab monotherapy is not a suitable first-line treatment because of its insufficient effectiveness, even though their PD-L1 TPS was high.
- Published
- 2019
25. Histologic transformation of epidermal growth factor receptor-mutated lung cancer
- Author
-
Daichi Fujimoto, Hiroaki Akamatsu, Takeshi Morimoto, Kazushige Wakuda, Yuki Sato, Yoshitaka Kawa, Toshihide Yokoyama, Motohiro Tamiya, Ryota Hiraoka, Naoki Shingu, Hideki Ikeda, Akihiro Tamiya, Masaki Kanazu, Eisaku Miyauchi, Satoru Miura, Masaaki Yanai, Makiko Yomota, Ryotaro Morinaga, Takashi Yokoi, Akito Hata, Hidekazu Suzuki, Hirotaka Matsumoto, Shinya Sakata, Naoki Furuya, Yuhei Harutani, Ichiro Nakachi, Ayumu Otsuki, Shinya Uematsu, Satoshi Hara, Keiki Yokoo, Takeya Sugimoto, and Nobuyuki Yamamoto
- Subjects
ErbB Receptors ,Cancer Research ,Lung Neoplasms ,Oncology ,Carcinoma, Non-Small-Cell Lung ,Mutation ,Humans ,Immune Checkpoint Inhibitors ,Protein Kinase Inhibitors ,Retrospective Studies - Abstract
This study aimed to determine the incidence and clinical course of epidermal growth factor receptor (EGFR)-mutated lung cancer with histologic transformation (HT).We conducted a multicentre, retrospective, cohort study of patients with advanced EGFR-mutated lung cancer who received EGFR-tyrosine kinase inhibitors (TKIs) between 2012 and 2019. The primary outcome was the incidence of HT. The secondary outcome was treatment efficacy in patients with HT.In total, 6356 patients were enrolled. In 2624 patients, the histological type was proven by rebiopsy after acquiring resistance to EGFR-TKIs. Among them, 74 patients had HT (incidence rate: 2.8% [95% confidence interval: 2.3%-3.5%]). The median progression-free survival after EGFR-TKIs and first-line therapy after confirming HT was 10.4 and 4.4 months, respectively, which was not significantly different between patients with transformation to high-grade neuroendocrine carcinoma and those with transformation to another subtype of non-small cell lung cancer. Overall survival after confirming HT was 12.2 months. Twenty-seven patients received immune checkpoint inhibitors: 6 and 21 received immune checkpoint inhibitors before and after confirming HT, respectively. No patients achieved 1-year progression-free survival. The median progression-free survival after immune checkpoint inhibitor therapy after confirming HT was 1.6 months.HT occurred in approximately 3% of EGFR-mutated patients who developed resistance to EGFR-TKIs. Cytotoxic agents are likely to be effective in patients with HT. However, the therapeutic effectiveness of immune checkpoint inhibitors was limited in these patients. Given the rarity of HT and absence of prospective trials, our findings are important to inform the treatment of these patients.
- Published
- 2021
26. Detection of Congestive Heart Failure and Myocardial Dysfunction in Cats With Cardiomyopathy by Using Two-Dimensional Speckle-Tracking Echocardiography
- Author
-
Ryohei Suzuki, Hirotaka Matsumoto, Yunosuke Yuchi, Takahiro Saito, Takahiro Teshima, Hidekazu Koyama, and Haruka Kanno
- Subjects
medicine.medical_specialty ,restrictive cardiomyopathy ,Veterinary medicine ,Cardiomyopathy ,cat ,Speckle tracking echocardiography ,heart ,Asymptomatic ,strain ,Internal medicine ,SF600-1100 ,medicine ,Left atrial enlargement ,cardiovascular diseases ,feline ,health care economics and organizations ,Original Research ,right heart function ,CATS ,General Veterinary ,business.industry ,Restrictive cardiomyopathy ,Hypertrophic cardiomyopathy ,hypertrophic cardiomyopathy ,myocardial function ,medicine.disease ,Heart failure ,cardiovascular system ,Cardiology ,Veterinary Science ,medicine.symptom ,business ,human activities ,circulatory and respiratory physiology - Abstract
Congestive heart failure (CHF) is a life-threatening condition in cats with cardiomyopathy. We hypothesized that myocardial dysfunction may induce progression to CHF pathophysiology in cats with cardiomyopathy. However, no previous studies have evaluated the involvement of myocardial dysfunction in cats with CHF. In this study, we aimed to evaluate the relationship between CHF and myocardial function assessed using two-dimensional speckle-tracking echocardiography (2D-STE). Sixteen client-owned healthy cats and 32 cats with cardiomyopathy were enrolled in this study. Cats were classified into three groups: healthy cats, cardiomyopathy without CHF (CM group), and cardiomyopathy with CHF (CHF group). Left ventricular (LV) longitudinal and circumferential strains (SL and SC, respectively), and right ventricular (RV) SL were measured using 2D-STE. Logistic regression analysis was performed to assess the relationship between CHF and echocardiographic variables, including 2D-STE. Results comparing the healthy cats and CM vs. CHF groups showed that increased left atrial to aortic diameter ratio and decreased LV apical SC were significantly associated with the existence of CHF (odds ratio [95% confidence interval]: 1.40 [1.16–1.78] and 1.59 [1.06–2.36], respectively). Results comparing the CM vs. CHF group showed that increased end-diastolic RV internal dimension and decreased RV SL were significantly associated with the existence of CHF (odds ratio: 1.07 [1.00–1.13] and 1.34 [1.07–1.68], respectively). Left atrial enlargement and depressed LV apical myocardial function may be useful tools for predicting the progression to CHF in cats. Furthermore, RV enlargement and dysfunction may lead to the onset of CHF in asymptomatic cats with cardiomyopathy.
- Published
- 2021
27. Investigation of the influence of manual ventilation-controlled respiration on right ventricular pressure-volume loops and echocardiographic variables in healthy anesthetized dogs
- Author
-
Hirotaka Matsumoto, Ryohei Suzuki, Takahiro Teshima, Hidekazu Koyama, and Yunosuke Yuchi
- Subjects
medicine.medical_specialty ,General Veterinary ,Ventricular function ,business.industry ,Heart Ventricles ,Respiration ,Ventricular Dysfunction, Right ,Stroke Volume ,General Medicine ,Stroke volume ,Dogs ,Volume (thermodynamics) ,Echocardiography ,Internal medicine ,medicine ,Ventricular pressure ,Cardiology ,Ventricular Function, Right ,Ventricular Pressure ,Animals ,Dog Diseases ,Prospective Studies ,Manual ventilation ,business - Abstract
OBJECTIVE To evaluate the influence of manual ventilation-controlled respiration on right ventricular (RV) pressure-volume loop–derived and echocardiographic variables in dogs. ANIMALS 8 healthy, anesthetized Beagles. PROCEDURES In a prospective experimental study, pressure-volume catheters were percutaneously inserted into the right ventricle of each dog, and manual ventilation was performed; RV pressure-volume loop (hemodynamic) data and conventional echocardiographic variables were assessed. Two-dimensional speckle tracking echocardiography–derived RV strain (RVS) and RV systolic strain rate (RVSR) were obtained with RV free wall–only analysis (free wall) and RV global analysis (RVGA; interventricular septum). Variables were compared between end-inspiratory and end-expiratory phases of respiration by statistical methods. Multiple regression analysis was used to assess associations between selected hemodynamic and echocardiographic variables. RESULTS The RV pressure significantly increased, and RV volume, stroke volume, tricuspid annular plane systolic excursion, RV fractional area change, peak myocardial systolic velocity of the lateral tricuspid annulus, and RV free wall only–assessed RVS and RVSR significantly decreased in the inspiratory phase, compared with the expiratory phase. There were no significant differences in end-systolic elastance or RVGA-assessed RVS or RVSR between respiratory phases. The RVGA-assessed RVSR was significantly associated with stroke volume and end-systolic elastance. CONCLUSIONS AND CLINICAL RELEVANCE Specific RV echocardiographic variables were significantly affected by respiration. In contrast, RVS and RVSR determined with RVGA were not affected by respiration and were associated with hemodynamic indicators of RV contractility.
- Published
- 2021
28. A Case of a Small-Breed Dog with Diet-Related Dilated Cardiomyopathy Showing Marked Improvements in Cardiac Morphology and Function after Dietary Modification
- Author
-
Takahiro Saito, Ryohei Suzuki, Yunosuke Yuchi, Yuyo Yasumura, Takahiro Teshima, Hirotaka Matsumoto, and Hidekazu Koyama
- Subjects
General Veterinary - Abstract
An 11-year-old intact female Papillion weighing 2.1 kg was referred to our institution with the main complaint of shallow, rapid breathing. At the first visit (day 0), although clinical signs improved due to the use of medication from the primary hospital, transthoracic radiography and echocardiography revealed left heart enlargement and left ventricular dysfunction. A clinical diagnosis of dilated cardiomyopathy (DCM) was made and oral administration of pimobendan, temocapril, and taurine was initiated. However, on day 10, the respiratory status worsened and furosemide was prescribed. On day 54, no significant improvement in heart size was observed. Additionally, the diet that this patient received met the recommendation for diet-related DCM by the U.S. Food and Drug Administration, and the patient’s diet was changed from a grain-free diet to a grain-containing diet. On day 1191, the patient’s respiratory status was stable and no clinical signs were observed. Transthoracic radiography and echocardiography revealed an improvement in left heart size. Additionally, improvements in the left and right ventricular myocardial strains were observed after changing the diet. We suggest that it may be necessary to suspect a dietary association with dilated cardiomyopathy, and a good prognosis might be expected by dietary modification, even in small-breed dogs.
- Published
- 2022
29. First-Line Pembrolizumab Monotherapy for Advanced NSCLC With Programmed Death-Ligand 1 Expression Greater Than or Equal to 50%: Real-World Study Including Older Patients in Japan
- Author
-
Yasushi Goto, Atsuhisa Tamura, Hirotaka Matsumoto, Kazutoshi Isobe, Tomohiro Ozaki, Melissa L. Santorelli, Kazuko Taniguchi, Tetsu Kamitani, Masato Irisawa, Kingo Kanda, Machiko Abe, Thomas Burke, and Hiroshi Nokihara
- Subjects
Pulmonary and Respiratory Medicine ,Oncology - Abstract
Pembrolizumab became available in Japan in February 2017 for first-line monotherapy of unresectable advanced and metastatic NSCLC with programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) greater than or equal to 50%. This retrospective chart review study aimed to describe real-world clinical outcomes of first-line pembrolizumab monotherapy, including for patients 75 years or older, who are under-represented in clinical trials.We identified patients (≥20 y old) at 23 sites initiating first-line pembrolizumab monotherapy from July 1, 2017, to December 20, 2018, for stages IIIB, IIIC, and IV NSCLC with PD-L1 TPS greater than or equal to 50% and Eastern Cooperative Oncology Group performance status of 0 to 2 or unknown. Patients with actionable genomic alterations (Of 441 eligible patients (78% men), 303 (69%) were younger than 75 years and 138 (31%) were 75 years or older; median age was 70 years. With median follow-up of 13.5 months, median overall survival (OS) was not reached (NR); 12- and 24-month OS rates were 72% and 58%, respectively. For ages younger than 75 and 75 years or older, median OS was NR and 23.5 months (95% confidence interval: 16.2-NR), respectively; 12-month OS rates were 74% and 67% and 24-month OS rates were 62% and 48%, respectively. Median real-world progression-free survival was similar in the two age groups (10.1 and 9.5 mo, respectively), as was median real-world time on treatment with pembrolizumab (5.7 and 5.6 mo).These findings complement clinical trial results, adding real-world evidence supporting benefits of first-line pembrolizumab monotherapy for advanced NSCLC with PD-L1 TPS greater than or equal to 50%, including for patients 75 years or older.
- Published
- 2022
30. Beraprost Sodium for Pulmonary Hypertension in Dogs: Effect on Hemodynamics and Cardiac Function
- Author
-
Ryohei Suzuki, Yunosuke Yuchi, Takahiro Saito, Yuyo Yasumura, Takahiro Teshima, Hirotaka Matsumoto, and Hidekazu Koyama
- Subjects
General Veterinary ,dog ,impedance ,myocardial strain ,post-capillary ,pre-capillary ,prostacyclin ,pulmonary circulation ,pulmonary vasodilator ,speckle-tracking echocardiography ,systemic circulation ,Animal Science and Zoology - Abstract
Pulmonary hypertension (PH) is a fatal condition that affects many dogs. In humans, PH is often treated with beraprost sodium (BPS). However, the effectiveness of BPS for canine PH has not been established. This study aimed to evaluate the clinical and cardiovascular response of BPS in canine patients with PH of various causes. Sixteen dogs with PH (post-capillary PH, n = 8; pre-capillary PH, n = 8) were included. BPS was continuously administered twice daily at 15 µg/kg. All dogs underwent echocardiography, including speckle-tracking analysis and blood pressure measurement, before and after BPS administration. Continuous BPS administration (range: 13.2–22.0 µg/kg) significantly decreased the pulmonary and systemic vascular impedance and increased left and right ventricular myocardial strain. In dogs with post-capillary PH, BPS administration caused no significant worsening of the left atrial pressure indicators. No side effects of BPS were observed in any dog. BPS also improved cardiac function and pulmonary circulation through pulmonary vasodilation, suggesting that BPS may be an additional treatment option for canine PH of various causes. Particularly, BPS increased left ventricular function and systemic circulation without worsening the left heart loading condition in dogs with post-capillary PH.
- Published
- 2022
31. Influence of heart rate on right ventricular function assessed by right heart catheterization and echocardiography in healthy anesthetized dogs
- Author
-
Yunosuke Yuchi, Ryohei Suzuki, Haruka Kanno, Takahiro Saito, Takahiro Teshima, Hirotaka Matsumoto, and Hidekazu Koyama
- Subjects
Cardiac Catheterization ,Dogs ,General Veterinary ,Echocardiography ,Heart Rate ,Heart Ventricles ,Ventricular Dysfunction, Right ,Body Weight ,Ventricular Function, Right ,Animals ,Stroke Volume ,General Medicine ,Dog Diseases - Abstract
Background Right ventricular (RV) functional assessment has received considerable attention in veterinary medicine since various diseases, such as cardiovascular, respiratory, endocrine, and neoplastic disease, may affect RV function. Heart rate (HR) is an important factor that can influence RV function through changes in loading condition and contractility. However, no study has yet evaluated the association between HR and RV function in the same individuals. This study aimed to evaluate the influence of elevated HR on RV function using right heart catheterization and echocardiography, and investigate the association between right heart catheterization and echocardiographic indices. Results Right atrial pacing was performed in eight dogs at 120, 140, 160, and 180 bpm. With an increase in HR, the RV systolic volume, RV diastolic volume, and stroke volume significantly decreased; however, the cardiac output, end-systolic elastance (Ees), and effective arterial elastance (Ea) significantly increased. Significant changes were not observed in RV pressure and Ees/Ea. The RV area normalized by body weight, RV fractional area change normalized by body weight (RV FACn), and tricuspid annular plane systolic excursion normalized by body weight (TAPSEn) significantly decreased with increased HR. Peak systolic myocardial velocity of the lateral tricuspid annulus (RV s’), RV strain, and RV strain rate of only the RV free wall analysis (RV-SrL3seg) showed no significant changes with the increase in HR; however, there was an increase in the RV strain rate of the RV global analysis (RV-SrL6seg). Multiple regression analysis revealed that HR, RV FACn, and RV- SrL6seg had significant associations with the Ees, and the TAPSEn and RV-SrL3seg with Ees/Ea. Conclusions Decreased venous return and shortened relaxation time decreased the RV FAC, TAPSE, RV s’, and RV strain, and might underestimate the RV function. Ees increased with the increase in HR, reflecting the myocardial force-frequency relation; as a result, RV-SrL6seg could be a useful tool for Ees estimation. Additionally, the RV-SrL3seg could detect RV performance, reflecting the balance between RV contractility and RV afterload.
- Published
- 2021
32. Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON)
- Author
-
Hirotaka Matsumoto, Yoshihiko Taniguchi, Shunsuke Teraoka, Kenji Nagata, Asuka Okada, Daisuke Arai, Fujimoto Daichi, Go Saito, Eisaku Miyauchi, Toshihide Yokoyama, Hidekazu Suzuki, Takeshi Uenami, Yoshihiko Sakata, Takayuki Niitsu, Hayato Kawachi, Takashi Yokoi, Yuko Oya, Masaki Kokubo, and Shunichiro Iwasawa
- Subjects
Pulmonary and Respiratory Medicine ,Adult ,Cancer Research ,medicine.medical_specialty ,Durvalumab ,Lung Neoplasms ,Internal medicine ,Carcinoma, Non-Small-Cell Lung ,Medicine ,Humans ,Lung cancer ,Pneumonitis ,Aged ,Retrospective Studies ,Aged, 80 and over ,business.industry ,Incidence (epidemiology) ,Medical record ,Antibodies, Monoclonal ,Odds ratio ,Chemoradiotherapy ,Pneumonia ,Middle Aged ,medicine.disease ,Consolidation Chemotherapy ,Radiation Pneumonitis ,Oncology ,Non small cell ,Neoplasm Recurrence, Local ,business - Abstract
The incidence of real-world pneumonitis and durvalumab rechallenge during chemoradiotherapy and durvalumab consolidation for non-small cell lung cancer is unknown.We retrospectively evaluated the medical records of 302 consecutive patients diagnosed with non-small cell lung cancer who started chemoradiotherapy between May 2018 and May 2019.Median age was 70 (range: 40-87) years. Volume of lung parenchyma that received 20 Gy (V20) exceeded 35% in 2% and mean lung dose exceeded 20 Gy in 1% of patients. Durvalumab consolidation was delivered to 225 patients (75%). Overall, 83% (n = 251), 34% (n = 103), 7% (n = 21), and 1% (n = 4) of the patients developed any grade of pneumonitis, symptomatic pneumonitis, ≥grade 3 pneumonitis, and fatal (grade 5) pneumonitis, respectively. Corticosteroids were administered to 25% of the patients to treat pneumonitis. Multivariate analysis identified the predictive factors for the development of symptomatic pneumonitis: V20 Gy or more ≥ 25% (odds ratio [OR]: 2.37, P = 0.008) and mean lung dose (MLD) ≥ 10 Gy (OR: 1.93, P 0.0047). Of the 52 patients who received corticosteroids for pneumonitis after durvalumab initiation, 21 were rechallenged with durvalumab. Overall, 81% of patients met the PACIFIC study's rechallenge criteria and did not experience a severe pneumonitis relapse.High V20 and MLD were independent risk factors of symptomatic pneumonitis. More than 80% of the patients who were rechallenged with durvalumab after pneumonitis met the PACIFIC study's rechallenge criteria. Consequently, severe relapse did not occur. Cooperation between radiation and medical oncologists is important for safe chemoradiotherapy and the safe completion of durvalumab consolidation therapy.
- Published
- 2021
33. Immunomodulatory Effects of Canine Adipose Tissue Mesenchymal Stem Cell-Derived Extracellular Vesicles on Stimulated CD4
- Author
-
Takahiro, Teshima, Yunosuke, Yuchi, Ryohei, Suzuki, Hirotaka, Matsumoto, and Hidekazu, Koyama
- Subjects
CD4-Positive T-Lymphocytes ,Immunosuppression Therapy ,Extracellular Vesicles ,Interferon-gamma ,Dogs ,Adipose Tissue ,Tumor Necrosis Factor-alpha ,Primary Cell Culture ,Animals ,Mesenchymal Stem Cells ,Cells, Cultured ,Coculture Techniques ,Research Article - Abstract
Adipose tissue-derived mesenchymal stem cells (ADSCs) have anti-inflammatory and immunomodulatory characteristics. Many studies have suggested that the immunomodulation of ADSCs is largely mediated by secreted paracrine factors. Various factors are secreted from ADSCs, among which extracellular vesicles are considered to play a major role in the communication between ADSCs and target cells. Several studies have reported the function of canine ADSC-derived extracellular vesicles (cADSC-EVs), but few studies have reported the immunomodulatory effects of cADSC-EVs on immune cells. The purpose of this study was to investigate the effects of cADSC-EVs on in vitro-stimulated CD4+ T cells isolated from peripheral blood mononuclear cells (PBMCs). cADSC-EVs were isolated from cADSCs under naive conditions or primed conditions by tumor necrosis factor-α (TNFα) and interferon-γ (IFNγ). The expression levels of several microRNAs in cADSC-EVs were altered by priming with TNFα and IFNγ. Culturing PBMCs stimulated with concanavalin A in the presence of naive or primed cADSC-EVs inhibited the differentiation of PBMCs and CD4+ T cells and promoted apoptosis of PBMCs. CD4+, CD8+, and CD4+CD8+ T cells were decreased, while CD3+CD4−CD8− T cells were increased. T helper (Th) 1, Th2, Th17, and regulatory T (Treg) cells were analyzed by flow cytometry. cADSC-EVs inhibited the proliferation of Th1 and Th17 cells and enhanced Th2 and Treg cell proliferation. However, CD4+ T cells that had incorporated labeled cADSC-EVs comprised only a few percent of all cells. Therefore, these responses of stimulated CD4+ T cells may be due to not only direct effects of cADSC-EVs but also to indirect effects through interactions between cADSC-EVs and other immune cells. In conclusion, cADSC-EVs exert immunosuppressive effects on stimulated CD4+ T cells in vitro. These findings may be useful for further studies of immune diseases.
- Published
- 2021
34. Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001)
- Author
-
Toru Kumagai, Masaki Kanazu, Daichi Fujimoto, Akihiro Tamiya, Hirotaka Matsumoto, Toshihide Yokoyama, Junji Uchida, Satoshi Hara, Mitsunori Morita, Yoshihiko Taniguchi, Motohiro Tamiya, Nobuhiko Sawa, Ryota Kominami, Kazutaka Hosoya, Yoshinori Kinoshita, Katsuya Hirano, Hidekazu Suzuki, Tomonori Hirashima, and Yasushi Fukuda
- Subjects
Adult ,Male ,0301 basic medicine ,medicine.medical_specialty ,Lung Neoplasms ,Pembrolizumab ,Antibodies, Monoclonal, Humanized ,Gastroenterology ,B7-H1 Antigen ,03 medical and health sciences ,Antineoplastic Agents, Immunological ,0302 clinical medicine ,Carcinoma, Non-Small-Cell Lung ,Internal medicine ,medicine ,Carcinoma ,Humans ,Pharmacology (medical) ,Progression-free survival ,Lung cancer ,Adverse effect ,Aged ,Pneumonitis ,Aged, 80 and over ,Pharmacology ,Predictive marker ,business.industry ,Retrospective cohort study ,Middle Aged ,medicine.disease ,Treatment Outcome ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Female ,business - Abstract
Objectives As first line therapy, pembrolizumab provides longer progression free survival (PFS) and overall survival (OS) than platinum doublets in programmed death ligand 1 (PD-L1)-positive non-small cell lung cancer (NSCLC) with tumor propensity scores (TPS) ≥50%. However, clinical trials do not represent real-world patients. Materials and Methods This multicenter retrospective study conducted across 11 medical centers in Japan analyzed clinical data from patients receiving first-line pembrolizumab for NSCLC between February 1, 2017 and April 30, 2018. The efficacy, safety, and suitability of pembrolizumab monotherapy were evaluated. Results The median age of the 213 enrolled patients was 71 (range: 39–91) years. Among them, 176 (82.6%) were male, 20 (9.4%) were never smokers (median Brinkman index: 900), 172 (80.8%) had an ECOG PS of 0–1, 55 (25.8%) had squamous-cell carcinoma (SQ). PD-L1 TPS were 50–74%, 75–89%, and 90–100% in 97 (45.5%), 47 (22.1%), and 69 (32.4%) patients, respectively. Adverse events (AEs) of grades ≥3 were observed in 39 (18.3%) patients. Pneumonitis was the most common severe AE, occurring in 10 patients (4.7%) including 1 with grade 4 toxicity; no severe AE-related deaths occurred. The overall response rate, median PFS, and median OS was 51.2%, 8.3 months, and 17.8 months, respectively. On multivariate analysis, ECOG PS (0–1 vs. ≥2: HR: 1.69, 95.0% CI: 1.05–2.72; p = 0.03138), CRP/Alb (
- Published
- 2019
35. Estimation of population genetic parameters using an EM algorithm and sequence data from experimental evolution populations
- Author
-
Yasuhiro Kojima, Hisanori Kiryu, and Hirotaka Matsumoto
- Subjects
0106 biological sciences ,Statistics and Probability ,Population ,010603 evolutionary biology ,01 natural sciences ,Biochemistry ,Evolution, Molecular ,03 medical and health sciences ,Data sequences ,Gene Frequency ,Effective population size ,Expectation–maximization algorithm ,Statistics ,Animals ,education ,Molecular Biology ,Allele frequency ,030304 developmental biology ,Mathematics ,Population Density ,0303 health sciences ,education.field_of_study ,Experimental evolution ,Models, Genetic ,Computational Biology ,Heavy traffic approximation ,Confidence interval ,Computer Science Applications ,Computational Mathematics ,Genetics, Population ,Computational Theory and Mathematics ,Drosophila ,Algorithms - Abstract
Motivation Evolve and resequence (E&R) experiments show promise in capturing real-time evolution at genome-wide scales, enabling the assessment of allele frequency changes SNPs in evolving populations and thus the estimation of population genetic parameters in the Wright–Fisher model (WF) that quantify the selection on SNPs. Currently, these analyses face two key difficulties: the numerous SNPs in E&R data and the frequent unreliability of estimates. Hence, a methodology for efficiently estimating WF parameters is needed to understand the evolutionary processes that shape genomes. Results We developed a novel method for estimating WF parameters (EMWER), by applying an expectation maximization algorithm to the Kolmogorov forward equation associated with the WF model diffusion approximation. EMWER was used to infer the effective population size, selection coefficients and dominance parameters from E&R data. Of the methods examined, EMWER was the most efficient method for selection strength estimation in multi-core computing environments, estimating both selection and dominance with accurate confidence intervals. We applied EMWER to E&R data from experimental Drosophila populations adapting to thermally fluctuating environments and found a common selection affecting allele frequency of many SNPs within the cosmopolitan In(3R)P inversion. Furthermore, this application indicated that many of beneficial alleles in this experiment are dominant. Availability and implementation Our C++ implementation of ‘EMWER’ is available at https://github.com/kojikoji/EMWER. Supplementary information Supplementary data are available at Bioinformatics online.
- Published
- 2019
36. Auswirkungen der Rebiopsie auf die Prognose von Patienten mit fortgeschrittenem nicht kleinzelligem Bronchialkarzinom nach Behandlung mit epidermalem Wachstumsfaktor-Rezeptor-Tyrosinkinase-Hemmer: ein systematischer Überblick
- Author
-
Katsuya Hirano, Toshiyuki Morisawa, Takuma Imakita, Yuki Kataoka, Hirotaka Matsumoto, and Azusa Sakurai
- Abstract
Hintergrund: Osimertinib, ein epidermaler Wachstumsfaktorrezeptor-Tyrosinkinasehemmer (Epidermal Growth Factor Receptor-Tyrosine-kinase Inhibitor, EGFR-TKI) der 3. Generation, ist mittlerweile die Standardtherapie in Fällen, in denen die Rebiopsie nach der Erstlinienbehandlung mit EGFR-TKI eine T790M-Mutation ergibt. Die Prognose der Patienten nach Rebiopsie, dem wichtigsten Outcome bei Krebspatienten, wurde bislang jedoch nicht ausreichend beschrieben. Die vorliegende systematische Übersichtsarbeit sollte klären, ob die Rebiopsie bei Patienten, die gegenüber den EGFR-TKI der 1. und 2. Generation refraktär sind, zu einer verbesserten Prognose beiträgt. Methoden: Mithilfe freier Wort- und Kontrollbegriffe im Zusammenhang mit «nicht kleinzelligem Bronchialkarzinom» und «Rebiopsie» suchten wir Studien aus dem Medical Literature Analysis and Retrieval System Online über PubMed, Embase, Cochrane Central Register of Controlled Trials und die World Health Organization International Clinical Trials Registry Platform. Eingeschlossen wurden Kohortenstudien und Fallberichte in englischer Sprache und es erfolgte eine Beurteilung, ob die jeweilige Studie unsere wissenschaftliche Fragestellung beantwortete. Ergebnisse: Von den 144 eingeschlossenen Studien enthielt nur eine Studie Angaben zur Prognose von Patienten mit/ohne Rebiopsie und zeigte, dass bei EGFR-TKI-refraktären Patienten mit nicht kleinzelligem Bronchialkarzinom das Überleben nach Krankheitsprogression (post-progression survival, PPS) bei Patienten, die eine Rebiopsie sowie eine Behandlung entsprechend dem Resistenzmechanismus erhalten hatten, signifikant länger war (medianes PPS: 24,2 Monate) als bei Patienten die eine Rebiopsie und Salvage-Therapie erhalten hatten (medianes PPS: 15,2 Monate, p = 0,002) und solchen ohne Rebiopsie (medianes PPS: 9,7 Monate, p < 0,001). Die meisten anderen Studien berichteten über die Nachweisrate von T790M-Mutationen oder das Rebiopsieverfahren. Schlussfolgerungen: Nur wenige der bisher durchgeführten Studien untersuchten die Wirksamkeit der Rebiopsie. Daher sind weitere Untersuchungen erforderlich, um die Prognose oder Nebenwirkungen der Rebiopsie zu ermitteln.
- Published
- 2019
37. The effect of environmental and biological factors on STT I and normal total tear protein concentration in Japanese black calves
- Author
-
Keiichi Matsuda, Takahiro Teshima, Hidekazu Koyama, Yukino Suyama, and Hirotaka Matsumoto
- Subjects
Male ,total tear protein ,040301 veterinary sciences ,Tear proteins ,Diagnostic Techniques, Ophthalmological ,Environment ,Biology ,Tear volume ,Tear production ,0403 veterinary science ,Biological Factors ,03 medical and health sciences ,lacrimal fluid ,Environmental temperature ,Animal science ,Time of day ,Reference Values ,Internal Medicine ,Animals ,Eye Proteins ,Lighting ,030304 developmental biology ,0303 health sciences ,General Veterinary ,Japanese Black cattle ,Age Factors ,Temperature ,Humidity ,04 agricultural and veterinary sciences ,Schirmer tear test ,Note ,eye diseases ,Japanese black calf ,ruminants ,Tears ,Reference values ,Cattle ,Female ,Barn (unit) - Abstract
To identify reference values for the Schirmer tear test I (STT I) in Japanese black cattle, investigate the effects of variables (sex, age, time of day, and environment in the barn including environmental temperature, humidity, illuminance, and ammonia concentration) on tear production, and determine total tear protein concentration. One-hundred-and-thirty-seven Japanese black cattle (67 females and 70 males, age 3-90 days) were evaluated. The mean STT I values was 18.9 ± 2.9 mm/min (n=263) and significant effects were age and ammonia concentration in the barn. Mean total tear protein concentration was 1.18 ± 0.30 mg/ml in healthy cattle older than 15 days (n=38). It was suggested that age and ammonia concentration are related to fluctuation of tear volume.
- Published
- 2019
38. Final progression-free survival analysis of phase II study with the combination therapy of DFP-14323, protease inhibitor, and low-dose afatinib as first-line therapy for common EGFR mutation–positive NSCLC
- Author
-
Hiroshige Yoshioka, Masahide Mori, Nobuyuki Katakami, Toshihide Yokoyama, Hiroyasu Kaneda, Hirotaka Matsumoto, Toru Kumagai, Kouji Yamamoto, and Cheng-long Huang
- Subjects
Cancer Research ,Oncology - Abstract
9111 Background: DFP-14323(INN: ubenimex) was developed as a biological response modifier and has been approved for maintenance therapy of AML in Japan. Ubenimex is an inhibitor of aminopeptidase N (APN), originated from Streptomyces olivoreticuli. APN is well known as one of the prognostic factors for several cancer types, including non-small-cell lung cancer (NSCLC). Meanwhile, afatinib is one of the standard treatments in NSCLC with EGFR mutation, but the toxicities often require dose reduction. Recently, it is suggested that reducing afatinib doses can decrease treatment-related adverse events without affecting efficacy. We aimed to examine efficacy of DFP-14323 with low-dose afatinib by conducting phase II study in patients with metastatic NSCLC harboring EGFR mutation. Methods: The study was a multi-center, single-arm, open-label phase II trial. Stage III/IV and treatment-naïve patients with common EGFR mutation-positive (L858R/19del) NSCLC were treated with DFP-14323 at a fixed dose of 10mg/day and afatinib at a starting dose of 20 mg/day until disease progression or intolerable toxicity. The primary endpoint was disease control rate (DCR), defined by sum the CR, PR and SD. The secondary endpoints were progression-free survival(PFS), overall response rate(ORR), N/L ratio, and safety. A sample size of 26 patients was determined, assuming a threshold DCR 70% and an expected DCR 90% with a two sided α error of 0.05 and a β error of 0.20, based on the Simon’s two stage design. Results: From July 2018 to March 2020, 26 patients were enrolled. A median age was 72 years (range, 53-82), 21(81%) were female, and 16 (62%) were never-smokers. Half of patients had Del-19 and other half had L858R. An efficacy analysis provided a DCR of 100% (previously reported) with 18 responders (ORR : 69%). Independent imaging evaluation at 72 weeks provided a median PFS was confirmed to be 16.6mts (95% CI 10.2, 22.9, median follow-up time for censored cases: 16.3mts). According to updated exploratory follow-up by physicians, as of the data cut-off of Dec 2021, median PFS was calculated 20.6 mts (95% CI, 12.6, 28.5, median follow-up time for censored case: 20.9mts). Seven Grade 3 adverse events were observed in 6patient(23%), and paronychias in 3 patients and diarrhea, stomatitis, dermatitis, and lymphocytopenia in 1 patient each. One paronychia was considered to be related to DFP-14323 and the other events to afatinib. No grade 4 or 5 adverse events were observed. One Grade 1 ILD was observed but recovered soon without treatment. Conclusions: Combination of DFP-14323 and low-dose afatinib has shown comparable potential as a first-line treatment for EGFR mutation positive NSCLC with feasible efficacy and good safety profile. We are planning a phase III study to evaluate this combination therapy as compared with other EGFR-TKIs. Clinical trial information: UMIN000033062.
- Published
- 2022
39. Impact of underrepresented populations on clinical outcomes of chemo-immunotherapy for extensive-stage small cell lung cancer: Real-world prospective cohort study
- Author
-
Motohiro Tamiya, Daichi Fujimoto, Hiroaki Akamatsu, Takeshi Morimoto, Akito Hata, Hirotaka Matsumoto, Atsushi Nakamura, Yuko Oya, Hisanori Amimoto, Haruko Daga, Hideki Ikeda, Shinya Sakata, Hidekazu Suzuki, Satoshi Ikeda, Yuhei Harutani, Ryota Hiraoka, Masaaki Yanai, Yoichiro Hamamoto, and Nobuyuki Yamamoto
- Subjects
Cancer Research ,Oncology - Abstract
8567 Background: Chemo-immunotherapy is the standard 1st-line therapy for patients with extensive-stage small cell lung cancer (ES-SCLC). Prospective data about underrepresented populations outside the clinical trial such as elderly or poor risk has not been revealed. Methods: We conducted a 32-hospitals prospective cohort study of consecutive patients with ES-SCLC who received carboplatin and etoposide with atezolizumab as 1st-line therapy between September 2019 and September 2020. The primary outcome was 6-months progression-free survival (PFS) probability of all patients. The secondary outcomes were overall survival (OS), PFS, time to treatment failure, objective response rate, safety, and differences in efficacy and safety depending on whether or not the key eligible study criteria of previous trials are met. Results: In total, 207 patients with ES-SCLC were analyzed. The median age was 72 years, and 64 patients (31%) were elderly (≥75 years). Most patients (89%) had a performance status (PS) of 0 or 1. As a result, 132 (64%) was categorized as eligible patients. The 6-months PFS probability of all patients was 38.8 % (95%CI:32.4-45.7%). Between eligible and ineligible patients, there was significant difference of patients who attained disease control (93% versus 77%, p = 0.002). Median PFS was significantly longer in eligible patients than ineligible patients (5.1 vs. 4.7 months; P =.03, HR 0.72 (95% CI 0.53–0.97)), and median OS was longer in eligible patients than ineligible patients, without any significant difference (15.8 vs. 13.1 months; P =.10, HR 0.73 (95% CI 0.51–1.07)). Survival analysis identified a PS score of 0-1 (HR: 0.60, 95% CI: 0.39-0.97, p = 0.03) as a significant predictor of better PFS, while PS score of 0-1 (HR: 0.51, 95% CI: 0.31-0.89, p = 0.01) and younger patients ( < 75 years) (HR: 0.66, 95% CI: 0.45-0.97, p = 0.03) as significant-good predictor of OS. The rate of severe AEs was higher in ineligible patients than in eligible (39% vs. 27%, respectively; p = 0.07), although the difference was not significant. Older age was significantly associated with severe AEs (p = 0.049). Conclusions: The real-world efficacy of chemo-immunotherapy for ES-SCLC was similar to that of pivotal clinical trials. However, trial-ineligible patients with ES-SCLC had poor treatment outcome and the higher rates of severe adverse events in this prospective cohort study. Our study suggests that positive results among the trial eligible patients may not translate to ineligible patients. Clinical trial information: UMIN000038064.
- Published
- 2022
40. Evaluation of a One-Step Real-Time PCR Kit Employing a Quick Fecal Processing Protocol for Rapidly Detecting the Norovirus Genome
- Author
-
Kenta Terauchi, Tomomi Yamazaki, Naomi Sakon, Hirotaka Matsumoto, Atsushi Sogabe, Toshihiro Kuroita, and Taku Arakawa
- Subjects
Protocol (science) ,Real-time polymerase chain reaction ,Computer science ,Norovirus ,medicine ,Computational biology ,medicine.disease_cause ,Genome ,Feces - Published
- 2018
41. Layer-specific myocardial function in asymptomatic cats with obstructive hypertrophic cardiomyopathy assessed using 2-dimensional speckle-tracking echocardiography
- Author
-
Hirotaka Matsumoto, Ryohei Suzuki, Takahiro Teshima, Hidekazu Koyama, Hiroki Yoshimatsu, Ayaka Niina, and Yohei Mochizuki
- Subjects
Male ,medicine.medical_specialty ,040301 veterinary sciences ,Cardiology ,cat ,Speckle tracking echocardiography ,Standard Article ,030204 cardiovascular system & hematology ,Cat Diseases ,Asymptomatic ,epicardial strain ,0403 veterinary science ,03 medical and health sciences ,strain ,0302 clinical medicine ,Internal medicine ,myocardium ,medicine ,Animals ,Circumferential strain ,cardiovascular diseases ,feline ,Retrospective Studies ,lcsh:Veterinary medicine ,CATS ,General Veterinary ,business.industry ,Significant difference ,endocardial strain ,Hypertrophic cardiomyopathy ,Heart ,04 agricultural and veterinary sciences ,Cardiomyopathy, Hypertrophic ,Myocardial function ,medicine.disease ,Standard Articles ,Echocardiography ,Case-Control Studies ,Asymptomatic Diseases ,Cats ,cardiovascular system ,lcsh:SF600-1100 ,Female ,SMALL ANIMAL ,medicine.symptom ,Obstructive hypertrophic cardiomyopathy ,business - Abstract
Background Hypertrophic cardiomyopathy (HCM), a primary disorder of the myocardium, is the most common cardiac disease in cats. However, determination of layer-specific myocardial function with 2D speckle-tracking echocardiography in cats with asymptomatic HCM has not yet been reported. Objectives To quantitatively measure layer-specific myocardial function of asymptomatic cats with HCM. Animals Ten client-owned, asymptomatic cats with obstructive HCM and 13 healthy cats. Methods A retrospective, case-control study. Cats underwent assessment of layer-specific myocardial function (whole, endocardial, and epicardial) in the longitudinal and circumferential directions by using 2D speckle-tracking echocardiography. Results Longitudinal strains were significantly lower in cats with HCM than controls in the whole (-15.5% vs -19.1%), endocardial (-18.3% vs -21.8%), and epicardial (-13.1% vs -16.8%) layers. Circumferential strains in whole and epicardial layers also were significantly lower in cats with HCM as compared with controls (-15.0% vs -20.2% and - 4.4% vs -9.4%, respectively). However, no significant difference was found between cats with HCM and controls in the global circumferential strain in the endocardial layer (-31.2% vs -34.2%). The circumferential endocardial-to-epicardial strain ratio was significantly higher in cats with HCM than in controls (6.1 vs 3.5). Conclusions and clinical importance Layer-specific myocardial function assessed by 2D speckle-tracking echocardiography differed in asymptomatic cats with obstructive HCM compared to controls despite their apparently normal systolic function, as determined by conventional echocardiography. The maintained endocardial circumferential strain and higher circumferential endocardial-to-epicardial strain ratio may reflect compensation for occult systolic dysfunction in cats with obstructive HCM.
- Published
- 2018
42. Sleep Stage Estimation Using ECG
- Author
-
Makikawa Masaaki, Hirotaka Matsumoto, Tianyi Wang, and Shima Okada
- Subjects
Estimation ,Frequency analysis ,medicine.diagnostic_test ,business.industry ,Decision tree ,Pattern recognition ,Electrooculography ,law.invention ,law ,medicine ,Poincaré plot ,Sleep (system call) ,Artificial intelligence ,Stage (hydrology) ,business - Abstract
Sleep stage judgement is not easy because it is difficult to measure biological signals. In addition, most people don’t know how to judge sleep stage. Therefore, this paper describes a method for estimation sleep stage using only an ECG. The used parameters from ECG was Poincare plot and DFA. The estimation model was decision tree. As a result, the best score achieved 74% accuracy. The accuracy of all other subjects achieved above 60%. The precision of WAKE and LIGHT all exceeded 50%. The estimation of REM was not working, but we are considering the accuracy is further improved by using the processing of individual differences and frequency analysis.
- Published
- 2020
43. A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC
- Author
-
Daichi Fujimoto, Satoru Miura, Kenichi Yoshimura, Kazushige Wakuda, Yuko Oya, Koji Haratani, Shoichi Itoh, Takehiro Uemura, Ryotaro Morinaga, Takayuki Takahama, Kazuhisa Nakashima, Motoko Tachihara, Go Saito, Junko Tanizaki, Kohei Otsubo, Satoshi Ikeda, Hirotaka Matsumoto, Satoshi Hara, Akito Hata, Takeshi Masuda, and Nobuyuki Yamamoto
- Subjects
Pulmonary and Respiratory Medicine ,Oncology ,Programmed Death-Ligand 1 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Immune checkpoint inhibitor ,Programmed Death-1 ,Pneumonitis ,Pembrolizumab ,RC254-282 - Abstract
Introduction: The real-world effectiveness of combination treatment with cytotoxic chemotherapy and programmed cell death protein-1 or programmed death-ligand 1 inhibitor for NSCLC, especially for the elderly (aged ≥75 y) or those with poor performance status (≥2), has not been fully elucidated. We investigated the real-world effectiveness and safety of this combination therapy in these populations. Methods: This multicenter retrospective study evaluated patients who are chemo-naïve with advanced NSCLC who received a combination of platinum, pemetrexed, and pembrolizumab between December 2018 and June 2019. This was an updated prespecified secondary analysis with the primary objective of investigating the safety and effectiveness in this cohort. Results: Overall, 299 patients were included. Multivariate analysis identified performance status (0–1) and programmed death-ligand 1 tumor proportion score (≥50%) as significant independent predictors of progression-free survival (p = 0.007, and p = 0.003, respectively). The incidence of severe adverse events (AEs) was higher in the elderly and those with poor performance status than in their younger and good performance status counterparts. A total of 71 patients developed AEs that led to treatment discontinuation, and AE-related treatment discontinuation occurred at a significantly higher rate in older patients (median [range]) (70 [46–82] y) than in younger patients (68 [31–84] y) (p
- Published
- 2022
44. Fecal microbiota transplantation as a new treatment for canine inflammatory bowel disease
- Author
-
Takahiro Teshima, Hidekazu Koyama, Yunosuke Yuchi, Hirotaka Matsumoto, Yasushi Kataoka, Ryoko Kibe, Ryohei Suzuki, and Ayaka Niina
- Subjects
medicine.medical_specialty ,biology ,business.industry ,Immunology ,Gastroenterology ,Fusobacteria ,Disease ,biology.organism_classification ,medicine.disease ,Applied Microbiology and Biotechnology ,Microbiology ,Inflammatory bowel disease ,Pathogenesis ,Diarrhea ,Fusobacterium ,Internal medicine ,medicine ,Microbiome ,medicine.symptom ,business ,Feces ,Food Science - Abstract
In human medicine, fecal microbiota transplantation (FMT) is an effective treatment for recurrent Clostridioides difficile infection. It has also been tested as a treatment for multiple gastrointestinal diseases, including inflammatory bowel disease (IBD). However, only a few studies have focused on the changes in the microbiome following FMT for canine IBD. Here, we performed FMT in nine dogs with IBD using the fecal matter of healthy dogs and investigated the subsequent changes in the fecal microbiome and clinical signs. In three dogs, the fecal microbiome was examined by 16S rRNA sequencing. Fusobacteria were observed at a low proportion in dogs with IBD. However, the post-FMT microbiome became diverse and showed a significant increase in Fusobacteria proportion. Fusobacterium was detected in the nine dogs by quantitative polymerase chain reaction. The proportion of Fusobacterium in the post-FMT fecal microbiome was significantly increased (p
- Published
- 2020
45. SCODE: an efficient regulatory network inference algorithm from single-cell RNA-Seq during differentiation
- Author
-
Chikara Furusawa, Hisanori Kiryu, Minoru S.H. Ko, Hirotaka Matsumoto, Norio Gouda, Shigeru B. H. Ko, Itoshi Nikaido, and Tetsutaro Hayashi
- Subjects
0301 basic medicine ,Statistics and Probability ,Source code ,Process (engineering) ,Computer science ,media_common.quotation_subject ,Cell ,Gene regulatory network ,Gene Expression ,Inference ,RNA-Seq ,Biology ,computer.software_genre ,Biochemistry ,Mice ,03 medical and health sciences ,medicine ,Animals ,Humans ,Gene Regulatory Networks ,Molecular Biology ,Gene ,Time complexity ,media_common ,Sequence Analysis, RNA ,Process (computing) ,Cell Differentiation ,Original Papers ,Expression (mathematics) ,Computer Science Applications ,Computational Mathematics ,030104 developmental biology ,medicine.anatomical_structure ,Computational Theory and Mathematics ,Ordinary differential equation ,Data mining ,Single-Cell Analysis ,computer ,Algorithm ,Algorithms ,Software - Abstract
The analysis of RNA-Seq data from individual differentiating cells enables us to reconstruct the differentiation process and the degree of differentiation (in pseudo-time) of each cell. Such analyses can reveal detailed expression dynamics and functional relationships for differentiation. To further elucidate differentiation processes, more insight into gene regulatory networks is required. The pseudo-time can be regarded as time information and, therefore, single-cell RNA-Seq data are time-course data with high time resolution. Although time-course data are useful for inferring networks, conventional inference algorithms for such data suffer from high time complexity when the number of samples and genes is large. Therefore, a novel algorithm is necessary to infer networks from single-cell RNA-Seq during differentiation.In this study, we developed the novel and efficient algorithm SCODE to infer regulatory networks, based on ordinary differential equations. We applied SCODE to three single-cell RNA-Seq datasets and confirmed that SCODE can reconstruct observed expression dynamics. We evaluated SCODE by comparing its inferred networks with use of a DNaseI-footprint based network. The performance of SCODE was best for two of the datasets and nearly best for the remaining dataset. We also compared the runtimes and showed that the runtimes for SCODE are significantly shorter than for alternatives. Thus, our algorithm provides a promising approach for further single-cell differentiation analyses.The R source code of SCODE is available at https://github.com/hmatsu1226/SCODE.
- Published
- 2017
46. Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
- Author
-
Masaki Kanazu, Tomonori Hirashima, Toru Kumagai, Ryota Kominami, Mitsunori Morita, Tadashi Ishida, Satoshi Hara, Yoshihiko Taniguchi, Keisuke Tomii, Nobuhiko Sawa, Takeshi Morimoto, Daichi Fujimoto, Hidekazu Suzuki, Kazutaka Hosoya, Akihiro Tamiya, Junji Uchida, Toshihide Yokoyama, Motohiro Tamiya, Hirotaka Matsumoto, Takeshi Makio, and Katsuya Hirano
- Subjects
0301 basic medicine ,Pulmonary and Respiratory Medicine ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,Drug-Related Side Effects and Adverse Reactions ,Pembrolizumab ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Carcinoma, Non-Small-Cell Lung ,Medicine ,Humans ,Prospective Studies ,Lung cancer ,Prospective cohort study ,Adverse effect ,Immune Checkpoint Inhibitors ,Aged ,Retrospective Studies ,Aged, 80 and over ,business.industry ,Retrospective cohort study ,Middle Aged ,medicine.disease ,Prognosis ,Rash ,Survival Rate ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Cohort ,Carcinoma, Squamous Cell ,Female ,medicine.symptom ,Nivolumab ,Neoplasm Recurrence, Local ,business ,Follow-Up Studies - Abstract
Introduction Previous studies have described an association between immune-related adverse events (irAEs) and better outcomes in patients administered nivolumab for advanced non–small-cell lung cancer. However, the patients in previous studies were not stratified by potential predictive factors, such as programmed cell death ligand 1 status and treatment lines. Additionally, little is known of whether the timing and type of irAEs can inform the prediction of outcomes. Patients and Methods We prospectively investigated the association between irAEs and outcomes in the single-center cohort that included patients administered nivolumab in the second or later line of therapy. Subsequently, we confirmed these findings in a retrospective multicenter cohort that included patients with programmed cell death ligand 1 tumor proportion score of ≥ 50% who had received first-line pembrolizumab. The primary outcome was progression-free survival (PFS). Results In the prospective cohort (n = 76), the median PFS was significantly longer for the patients experiencing irAEs within 2 weeks of beginning nivolumab compared with the PFS for those who did not (median, 5.0 months [95% confidence interval (CI), 2.1-8.6 months] vs. median, 2.0 months [95% CI, 1.9-2.5 months]; P = .046). The association was stronger with earlier (within 2 weeks) than with later (within 6 weeks) irAEs. In the retrospective cohort (n = 148), the median PFS was significantly longer for the patients with early irAEs (within 3 weeks) than for those without (median, not reached [95% CI, 5.9 months to not reached] vs. median, 6.9 months [95% CI, 4.2-9.7 months]; P = .04). Rash was common and a better predictor of outcomes in both cohorts. Conclusion Our results have provided firmer evidence of the association between the occurrence of irAEs and outcomes and suggest that early irAEs (especially rash) might better predict outcomes.
- Published
- 2019
47. An NMF-based approach to discover overlooked differentially expressed gene regions from single-cell RNA-seq data
- Author
-
Masaya Nakamura, Tsuyoshi Iida, Tetsutaro Hayashi, Hirotaka Matsumoto, Koki Tsuyuzaki, Haruka Ozaki, Itoshi Nikaido, Mana Umeda, and Hideyuki Okano
- Subjects
0303 health sciences ,Cell type ,Cell ,RNA ,RNA-Seq ,Computational biology ,Biology ,Neural stem cell ,Transcriptome ,03 medical and health sciences ,0302 clinical medicine ,medicine.anatomical_structure ,Gene expression ,medicine ,Methods Article ,Progenitor cell ,Gene ,030217 neurology & neurosurgery ,030304 developmental biology - Abstract
Single-cell RNA sequencing has enabled researchers to quantify the transcriptomes of individual cells, infer cell types and investigate differential expression among cell types, which will lead to a better understanding of the regulatory mechanisms of cell states. Transcript diversity caused by phenomena such as aberrant splicing events have been revealed, and differential expression of previously unannotated transcripts might be overlooked by annotation-based analyses. Accordingly, we have developed an approach to discover overlooked differentially expressed (DE) gene regions that complements annotation-based methods. Our algorithm decomposes mapped count data matrix for a gene region using non-negative matrix factorization, quantifies the differential expression level based on the decomposed matrix, and compares the differential expression level based on annotation-based approach to discover previously unannotated DE transcripts. We performed single-cell RNA sequencing for human neural stem cells and applied our algorithm to the dataset. We also applied our algorithm to two public single-cell RNA sequencing datasets correspond to mouse ES and primitive endoderm cells, and human preimplantation embryos. As a result, we discovered several intriguing DE transcripts, including a transcript related to the modulation of neural stem/progenitor cell differentiation.
- Published
- 2019
48. Morphine for dyspnoea in chronic obstructive pulmonary disease: a before-after efficacy study
- Author
-
Takuhiro Yamaguchi, Keisuke Ariyoshi, Satoru Iwase, Yasuo Kohashi, Yoshikazu Inoue, Sawako Kaku, Hiroshi Morishita, Mitsunori Nishikawa, Tatsuya Morita, Keita Hosoi, Yoshinobu Matsuda, Hirotaka Matsumoto, Kayo Kusama, and Shunsuke Oyamada
- Subjects
medicine.medical_specialty ,Evening ,Nausea ,Vital signs ,Medicine (miscellaneous) ,Anorexia ,030204 cardiovascular system & hematology ,03 medical and health sciences ,Pulmonary Disease, Chronic Obstructive ,0302 clinical medicine ,Internal medicine ,Medicine ,Humans ,030212 general & internal medicine ,Prospective Studies ,Adverse effect ,Morning ,COPD ,Morphine ,Oncology (nursing) ,business.industry ,General Medicine ,medicine.disease ,Analgesics, Opioid ,Medical–Surgical Nursing ,Dyspnea ,medicine.symptom ,business ,Somnolence - Abstract
ObjectivesDyspnoea in patients with chronic obstructive pulmonary disease (COPD) is frequent and often persists despite conventional treatment. This study aimed to evaluate the efficacy and safety of oral morphine for dyspnoea in Japanese COPD patients.MethodsWe conducted a multi-institutional, prospective, before–after study of morphine in COPD patients with dyspnoea at rest in seven hospitals. Patients received 12 mg of oral morphine per day (or 8 mg per day if low body weight or renal impairment). Primary outcome was change in the numerical rating scale (NRS) of current dyspnoea in the evening from Day 0 to Day 2. Secondary outcomes included changes in dyspnoea intensity in the evening from Day 0 to Day 1, dyspnoea intensity between the morning from Day 0 to Day 1 and Day 2, vital signs, nausea, somnolence, anorexia and other adverse events (AEs).ResultsA total of 35 patients were enrolled in this study between October 2014 and January 2018. One patient did not receive study treatment. Data from 34 patients was analysed. The NRS of dyspnoea intensity in the evening significantly decreased from 3.9 on Day 0 (95% CI: 3.1 to 4.8) to 2.4 on Day 2 (95% CI: 1.7 to 3.1; p=0.0002). Secondary outcomes significantly improved in a similar manner. There were no apparent changes in the mean scores of the opioid-related AEs and vital signs. One patient experienced grade 3 lung infection not associated with morphine. Other AEs were mild.ConclusionOral morphine is effective in alleviating dyspnoea in Japanese COPD patients.Trial registrationUMIN000015288 (http://www.umin.ac.jp/ctr/index.htm).
- Published
- 2019
49. Left ventricular geometric characteristics predict response to carvedilol in cats with asymptomatic hypertrophic obstructive cardiomyopathy caused by systolic anterior motion of the mitral valve
- Author
-
Ryohei Suzuki, Hirotaka Matsumoto, Yuyo Yasumura, Takahiro Teshima, Hidekazu Koyama, Takahiro Saito, and Yohei Mochizuki
- Subjects
Male ,medicine.medical_specialty ,geometry ,040301 veterinary sciences ,Adrenergic beta-Antagonists ,Diastole ,systolic anterior motion ,Hemodynamics ,carvedilol ,Cat Diseases ,Obstructive cardiomyopathy ,Asymptomatic ,0403 veterinary science ,03 medical and health sciences ,Internal medicine ,Mitral valve ,Internal Medicine ,hypertrophic obstructive cardiomyopathy ,Medicine ,Animals ,cardiovascular diseases ,feline ,Carvedilol ,030304 developmental biology ,Retrospective Studies ,0303 health sciences ,CATS ,General Veterinary ,business.industry ,Retrospective cohort study ,04 agricultural and veterinary sciences ,Cardiomyopathy, Hypertrophic ,Note ,medicine.anatomical_structure ,Echocardiography ,Cardiology ,cardiovascular system ,Cats ,Mitral Valve ,Female ,medicine.symptom ,business ,medicine.drug - Abstract
Beta-blockers are used to treat cats with hypertrophic obstructive cardiomyopathy (HOCM). However, there are various hemodynamic responses to beta-blockers. This retrospective study aimed to explore the relationship between the response to carvedilol and the presence of geometric abnormalities. Medical records were reviewed for 16 cats diagnosed with HOCM. Cats were divided into two groups based on the velocity of the left-ventricular outflow-tract after carvedilol treatment (responder: eight cats, non-responder: eight cats). Baseline intergroup comparison revealed that anterior mitral valve leaflet length and diastolic left-ventricular posterior-wall thickness were significantly greater in the non-responder group. Longer anterior mitral valve leaflet and thicker left-ventricular posterior-wall may cause poor response to carvedilol. Thus, these properties may predict a lack of response to carvedilol therapy.
- Published
- 2019
50. Molecular mechanism of lysophosphatidic acid-induced hypertensive response
- Author
-
Asuka Inoue, Hiroshi Yukiura, Satoshi Ishii, Kuniyuki Kano, Jerold Chun, Motomu Kanai, Junken Aoki, Takao Shimizu, and Hirotaka Matsumoto
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Fluorescent Antibody Technique ,lcsh:Medicine ,GTP-Binding Protein alpha Subunits, G12-G13 ,Article ,Mice ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,Lysophosphatidic acid ,medicine ,Animals ,lcsh:Science ,Receptor ,Adrenergic Agent ,rho-Associated Kinases ,Multidisciplinary ,Chemistry ,lcsh:R ,Disease Models, Animal ,030104 developmental biology ,medicine.anatomical_structure ,Endocrinology ,Blood pressure ,Rho kinase inhibitor ,Hypertension ,Molecular mechanism ,lcsh:Q ,lipids (amino acids, peptides, and proteins) ,Disease Susceptibility ,Lysophospholipids ,biological phenomena, cell phenomena, and immunity ,Signal transduction ,Biomarkers ,030217 neurology & neurosurgery ,Signal Transduction ,Blood vessel - Abstract
Lysophosphatidic acid (LPA) is a blood-derived bioactive lipid with numerous biological activities exerted mainly through six defined G protein-coupled receptors (LPA1-LPA6). LPA was first identified as a vasoactive compound because it induced transient hypertension when injected intravenously in rodents. Here, we examined the molecular mechanism underlying the LPA-induced hypertensive response. The LPA-induced hypertensive response was significantly attenuated by pretreatment with a Rho kinase inhibitor, which blocks Gα12/13 signaling. Consistent with this, the response was weakened in KO mice of LPA4, a Gα12/13-coupling LPA receptor. KO mice of another Gα12/13-coupling LPA receptor, LPA6, also showed an attenuated LPA-induced hypertensive response. However, LPA6 KO mice also displayed attenuated pressor responses to an adrenergic agent and abnormal blood vessel formation. Using several LPA analogs with varied affinity for each LPA receptor, we found a good correlation between the hypertensive and LPA4 agonistic activities. Incubated mouse plasma, which contained abundant LPA, also induced a hypertensive response. Interestingly the response was completely abolished when the plasma was incubated in the presence of an ATX inhibitor. Together, these results indicate that circulating LPA produced by ATX contributes to the elevation of blood pressure through multiple LPA receptors, mainly LPA4.
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.